<!DOCTYPE html><html><head><meta charSet="utf-8"/><meta name="viewport" content="user-scalable=yes, width=device-width, initial-scale=1, maximum-scale=2, viewport-fit=cover"/><link href="https://takeda-mo.mo.cloudinary.net" rel="dns-prefetch"/><link href="https://takeda-mo.mo.cloudinary.net" rel="preconnect"/><style>:root {
  --colorDarkGrey:#34373f;
  --colorSecondary:#ffffff;
  --textColor:#333333;
  --colorPrimaryActiveContrast:#ffffff;
  --colorPrimaryContrast:#ffffff;
  --colorDarkGreyContrast:#ffffff;
  --colorLightGrey:#edf2f4;
  --colorMediumGreyContrast:#ffffff;
  --colorMediumGrey:#8289A5;
  --colorPrimary:#bd120a;
  --colorLightGreyContrast:#34373f;
  --colorSecondaryContrast:#34373f;
  --colorPrimaryActive:#891515;
}</style><link rel="preload" href="/fonts/woff2/GothamSSm-Book_Web.woff2" as="font" crossorigin="" type="font/woff2"/><link rel="shortcut icon" href="/favicon.ico"/><link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png"/><title>Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology</title><meta name="robots" content="index,follow"/><meta name="description" content="Discover Takeda Oncology&#x27;s decades of leadership in oncology. Explore their approach, latest news, pipeline, and innovative therapies."/><meta property="og:title" content="Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology"/><meta property="og:description" content="Discover Takeda Oncology&#x27;s decades of leadership in oncology. Explore their approach, latest news, pipeline, and innovative therapies."/><meta property="og:url" content="https://www.takedaoncology.com/"/><meta property="og:image" content="http://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg"/><meta property="og:image:alt" content="Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology"/><meta property="og:image:secure_url" content="https://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg"/><meta property="og:image:type" content="image"/><meta property="og:image:width" content="4800"/><meta property="og:image:height" content="2700"/><link rel="canonical" href="https://www.takedaoncology.com/"/><meta name="next-head-count" content="21"/><script defer="" data-nscript="beforeInteractive">
window.aimDataLayer = window.aimDataLayer || [];
function aimTag() { aimDataLayer.push(arguments); }
// Transition event is temporary during a limited period of time to allow us to pull application cache from Legacy AIM Reader (v2) over to AIM Tag (v4)
aimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'transition');
aimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'pageview');
// If your contract includes signal, then callback will include personal information on the visitor
aimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'signal', function(err, success) {
    if (err) {
        // This will occur if we disable your API Key
        console.log(err);
    } else {
        console.log(success);
        if (success.identity_type === "AUT") {
            // Handle signal callback here
        }
    }
});
</script><script defer="" type="text/javascript" data-nscript="beforeInteractive">
function OptanonWrapper() { }
</script><script data-nscript="beforeInteractive">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WLM2GHB');</script><script data-nscript="beforeInteractive">
var _mtm = window._mtm = window._mtm || [];
_mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'});
var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];
g.async=true; g.src='https://cdn.matomo.cloud/takeda.matomo.cloud/container_8RFPFIX1.js'; s.parentNode.insertBefore(g,s);
</script><link rel="preload" href="/_next/static/css/c519d5e30826dfa8.css" as="style"/><link rel="stylesheet" href="/_next/static/css/c519d5e30826dfa8.css" data-n-g=""/><link rel="preload" href="/_next/static/css/c6727958a5da520b.css" as="style"/><link rel="stylesheet" href="/_next/static/css/c6727958a5da520b.css"/><link rel="preload" href="/_next/static/css/f714de409d1b43fb.css" as="style"/><link rel="stylesheet" href="/_next/static/css/f714de409d1b43fb.css"/><link rel="preload" href="/_next/static/css/99f1298953809fb9.css" as="style"/><link rel="stylesheet" href="/_next/static/css/99f1298953809fb9.css"/><link rel="preload" href="/_next/static/css/8a81431e0111eb38.css" as="style"/><link rel="stylesheet" href="/_next/static/css/8a81431e0111eb38.css"/><link rel="preload" href="/_next/static/css/ed452b8d3cb9b5f5.css" as="style"/><link rel="stylesheet" href="/_next/static/css/ed452b8d3cb9b5f5.css"/><link rel="preload" href="/_next/static/css/02de4b6bcecda68e.css" as="style"/><link rel="stylesheet" href="/_next/static/css/02de4b6bcecda68e.css"/><link rel="preload" href="/_next/static/css/334b3874b222d47d.css" as="style"/><link rel="stylesheet" href="/_next/static/css/334b3874b222d47d.css"/><link rel="preload" href="/_next/static/css/6ff744ee6873a788.css" as="style"/><link rel="stylesheet" href="/_next/static/css/6ff744ee6873a788.css"/><link rel="preload" href="/_next/static/css/35f0bf5638c2f65f.css" as="style"/><link rel="stylesheet" href="/_next/static/css/35f0bf5638c2f65f.css"/><link rel="preload" href="/_next/static/css/36d3bb1b647312d3.css" as="style"/><link rel="stylesheet" href="/_next/static/css/36d3bb1b647312d3.css"/><link rel="preload" href="/_next/static/css/0c89d452b222e8e2.css" as="style"/><link rel="stylesheet" href="/_next/static/css/0c89d452b222e8e2.css"/><link rel="preload" href="/_next/static/css/56e10993677736b5.css" as="style"/><link rel="stylesheet" href="/_next/static/css/56e10993677736b5.css"/><link rel="preload" href="/_next/static/css/454c4863b1d22146.css" as="style"/><link rel="stylesheet" href="/_next/static/css/454c4863b1d22146.css"/><link rel="preload" href="/_next/static/css/5fa28fb095095df8.css" as="style"/><link rel="stylesheet" href="/_next/static/css/5fa28fb095095df8.css"/><link rel="preload" href="/_next/static/css/1b4576b1bf4a91c6.css" as="style"/><link rel="stylesheet" href="/_next/static/css/1b4576b1bf4a91c6.css"/><link rel="preload" href="/_next/static/css/9f82b9d0d0c21666.css" as="style"/><link rel="stylesheet" href="/_next/static/css/9f82b9d0d0c21666.css"/><link rel="preload" href="/_next/static/css/f544ebc22208d8fd.css" as="style"/><link rel="stylesheet" href="/_next/static/css/f544ebc22208d8fd.css"/><link rel="preload" href="/_next/static/css/ef46db3751d8e999.css" as="style"/><link rel="stylesheet" href="/_next/static/css/ef46db3751d8e999.css"/><link rel="preload" href="/_next/static/css/697dd36401a33942.css" as="style"/><link rel="stylesheet" href="/_next/static/css/697dd36401a33942.css"/><link rel="preload" href="/_next/static/css/c3c237832837880a.css" as="style"/><link rel="stylesheet" href="/_next/static/css/c3c237832837880a.css"/><link rel="preload" href="/_next/static/css/b7f105bd9500c480.css" as="style"/><link rel="stylesheet" href="/_next/static/css/b7f105bd9500c480.css"/><link rel="preload" href="/_next/static/css/cb5012c0c2e9150c.css" as="style"/><link rel="stylesheet" href="/_next/static/css/cb5012c0c2e9150c.css"/><link rel="preload" href="/_next/static/css/f94747be08d67b50.css" as="style"/><link rel="stylesheet" href="/_next/static/css/f94747be08d67b50.css"/><link rel="preload" href="/_next/static/css/ce4e8d440c4d117e.css" as="style"/><link rel="stylesheet" href="/_next/static/css/ce4e8d440c4d117e.css"/><link rel="preload" href="/_next/static/css/08eb4b1e92fe81cb.css" as="style"/><link rel="stylesheet" href="/_next/static/css/08eb4b1e92fe81cb.css"/><link rel="preload" href="/_next/static/css/15ef2fffadd72147.css" as="style"/><link rel="stylesheet" href="/_next/static/css/15ef2fffadd72147.css"/><link rel="preload" href="/_next/static/css/d5a466a385fa8ca2.css" as="style"/><link rel="stylesheet" href="/_next/static/css/d5a466a385fa8ca2.css"/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script src="https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer&amp;target=ie11" defer="" nomodule="" data-nscript="beforeInteractive"></script><script src="https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer" defer="" type="module" data-nscript="beforeInteractive"></script><script src="https://cdn.cookielaw.org/consent/1c21da89-fd19-457f-a6d0-69a1c4fead2d/OtAutoBlock.js" defer="" type="text/javascript" data-nscript="beforeInteractive"></script><script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" defer="" data-document-language="true" type="text/javascript" charSet="UTF-8" data-domain-script="1c21da89-fd19-457f-a6d0-69a1c4fead2d" data-nscript="beforeInteractive"></script><script defer="" src="/_next/static/chunks/8913.8618515d6a868dda.js"></script><script defer="" src="/_next/static/chunks/1735.6e13465857a46e49.js"></script><script defer="" src="/_next/static/chunks/982.49d90b2e7c60d920.js"></script><script defer="" src="/_next/static/chunks/29107295.54c46f60208f68c8.js"></script><script defer="" src="/_next/static/chunks/3707.581b5e92eb05e247.js"></script><script defer="" src="/_next/static/chunks/8378.275f2173944fc013.js"></script><script defer="" src="/_next/static/chunks/1467.47739fc584c2757a.js"></script><script defer="" src="/_next/static/chunks/4676.f60b29e1327e8187.js"></script><script defer="" src="/_next/static/chunks/9669.c8815bc7bc3ead79.js"></script><script defer="" src="/_next/static/chunks/8212.48487cb9786df9db.js"></script><script defer="" src="/_next/static/chunks/9327.f98e8218a85cc756.js"></script><script defer="" src="/_next/static/chunks/8079.27f1c84ee15713c1.js"></script><script defer="" src="/_next/static/chunks/738.f9148f949790a9ae.js"></script><script defer="" src="/_next/static/chunks/675.a1a1af359fe4d930.js"></script><script defer="" src="/_next/static/chunks/286.3545219d6ff7852f.js"></script><script defer="" src="/_next/static/chunks/2066.c95332614bc5ec40.js"></script><script defer="" src="/_next/static/chunks/3829.7b1cdd8ec4cb42d9.js"></script><script defer="" src="/_next/static/chunks/7588.a4ac813d2e46add1.js"></script><script defer="" src="/_next/static/chunks/3477.fc7686ec2bfc4cbd.js"></script><script defer="" src="/_next/static/chunks/9362.cb2c1f208376aa61.js"></script><script defer="" src="/_next/static/chunks/9838.34be64ecf5398e95.js"></script><script defer="" src="/_next/static/chunks/288.133b7741cbb88b08.js"></script><script defer="" src="/_next/static/chunks/3644.41c81531f05f80c9.js"></script><script defer="" src="/_next/static/chunks/7707.00b790143b205e67.js"></script><script defer="" src="/_next/static/chunks/4492.d62d0a41ba6a3f4d.js"></script><script defer="" src="/_next/static/chunks/3559.c5f863fc7abca312.js"></script><script defer="" src="/_next/static/chunks/3439.2844afaaa351065f.js"></script><script defer="" src="/_next/static/chunks/5455.cd48f42775aee779.js"></script><script defer="" src="/_next/static/chunks/6978.7b1a4f1a33950375.js"></script><script defer="" src="/_next/static/chunks/8845.dcf92c65fc1b229d.js"></script><script defer="" src="/_next/static/chunks/9634.a0250f8010de76bc.js"></script><script defer="" src="/_next/static/chunks/9413.99fc3b9a6a9bfe5b.js"></script><script defer="" src="/_next/static/chunks/3085.1e018d7cfcba1d94.js"></script><script defer="" src="/_next/static/chunks/2600.bb529bdb71abf7ad.js"></script><script defer="" src="/_next/static/chunks/812.bc3fd270f49cb973.js"></script><script defer="" src="/_next/static/chunks/7871.fe47449ddf5756f2.js"></script><script defer="" src="/_next/static/chunks/4009.b9ca0a7800c0dc84.js"></script><script defer="" src="/_next/static/chunks/2255.ffe8f76c47cdaad9.js"></script><script defer="" src="/_next/static/chunks/6211.bda66a8a1fc8e747.js"></script><script defer="" src="/_next/static/chunks/6166.84d789d4bb423317.js"></script><script defer="" src="/_next/static/chunks/8211.73055784ab0ae98d.js"></script><script defer="" src="/_next/static/chunks/1118.b7a94127c8bbafda.js"></script><script defer="" src="/_next/static/chunks/5847.037fc13e40f17ded.js"></script><script defer="" src="/_next/static/chunks/3851.b798abbfd9b6d935.js"></script><script defer="" src="/_next/static/chunks/1078.da84bc00ff6589a4.js"></script><script defer="" src="/_next/static/chunks/283.12886359ee935697.js"></script><script defer="" src="/_next/static/chunks/5298.52a7022d1727d611.js"></script><script defer="" src="/_next/static/chunks/3029.f552db69430d366e.js"></script><script defer="" src="/_next/static/chunks/5866.0eac23fb033fc3f1.js"></script><script defer="" src="/_next/static/chunks/5724.5488b2011e94cf31.js"></script><script defer="" src="/_next/static/chunks/7133.6baf6024d2fdc8bc.js"></script><script defer="" src="/_next/static/chunks/6362.eff60ce13337ecb7.js"></script><script defer="" src="/_next/static/chunks/9457.ace3bca4eac3ffb2.js"></script><script src="/_next/static/chunks/webpack-74757dc52aef77e3.js" defer=""></script><script src="/_next/static/chunks/framework-ce84985cd166733a.js" defer=""></script><script src="/_next/static/chunks/main-d09ace4de2a9c53e.js" defer=""></script><script src="/_next/static/chunks/pages/_app-cd716749cbc36f2c.js" defer=""></script><script src="/_next/static/chunks/8660-4a197c146bc5993e.js" defer=""></script><script src="/_next/static/chunks/7557-1da5eb9c852f6287.js" defer=""></script><script src="/_next/static/chunks/pages/%5B%5B...slug%5D%5D-daf39028f5cf7841.js" defer=""></script><script src="/_next/static/K3VXqlfsDZXTEXydIA4dC/_buildManifest.js" defer=""></script><script src="/_next/static/K3VXqlfsDZXTEXydIA4dC/_ssgManifest.js" defer=""></script></head><body><div id="__next">
<!-- -->
<!-- -->
<!-- -->
<!-- -->
<!-- -->
<!-- -->
<!-- -->
<style type="text/css"> #onetrust-consent-sdk svg {display: inline;} </style><div id="root" data-sb-object-id="a8d23517-8dcf-4abb-bb2c-888f0fac92bc"><header data-sb-field-path="IV5sQe0KJfPcurPYxLZQeL:header" class="w-full shadow-lg flex items-center py-[20px] h-[90px] max-sm:h-[56px] px-[40px] max-sm:px-[20px] w-[100%] transition sticky z-[100] top-0 bg-white text-dark-grey"><a data-sb-field-path=".logo" class="flex items-center relative w-[96px] max-sm:w-[56px] ml-[-2px]" role="link" aria-label="Takeda Oncology" href="/"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:2.7972972972972974"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="Takeda logo" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU rounded-none" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover"/><noscript><img alt="Takeda logo" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU rounded-none" sizes="100vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0"/></noscript></span></div></a><div class="flex items-center ml-auto"><div class="relative max-sm:static"><form role="combobox" aria-expanded="false" aria-haspopup="listbox" aria-labelledby="autocomplete-165-label"><div><div class="flex flex-row items-center search"><button aria-label="Search" type="button" class="m-[10px]"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 22 22" class="w-[22px] h-[22px] fill-current"><path d="M12.43.27a7.39,7.39,0,0,1,2-.27,7.51,7.51,0,0,1,3.81,1A7.81,7.81,0,0,1,21,3.75a7.51,7.51,0,0,1,1,3.81,7.58,7.58,0,0,1-1,3.82,8.28,8.28,0,0,1-1.19,1.53,7.72,7.72,0,0,1-3.33,1.95,7.74,7.74,0,0,1-4.59-.19,7.64,7.64,0,0,1-2.26-1.3L1.17,21.8a.69.69,0,0,1-1,0,.69.69,0,0,1,0-1L8.63,12.4a7.64,7.64,0,0,1-1.3-2.26,7.45,7.45,0,0,1-.45-2.58,7.49,7.49,0,0,1,.26-2,7.72,7.72,0,0,1,2-3.33A8.28,8.28,0,0,1,10.62,1,7.45,7.45,0,0,1,12.43.27Zm-.4,13a6.15,6.15,0,0,0,4.81,0,6.12,6.12,0,0,0,2-1.33,6.24,6.24,0,0,0,1.33-2,6.1,6.1,0,0,0,.48-2.41,6.05,6.05,0,0,0-.48-2.4,6.24,6.24,0,0,0-3.3-3.3,6.27,6.27,0,0,0-4.81,0,6.24,6.24,0,0,0-2,1.33,6.12,6.12,0,0,0-1.33,2,5.89,5.89,0,0,0-.49,2.4A5.94,5.94,0,0,0,8.74,10,6.3,6.3,0,0,0,12,13.26Z"></path></svg></button><div class="overflow-hidden transition-all max-sm:block max-sm:absolute max-sm:left-0 max-sm:top-[55px] max-sm:w-full w-0 max-sm:h-0"><div class="h-[35px] max-sm:h-[53px] w-full p-[10px] max-sm:p-0 bg-white text-dark-grey border-b-[1px] max-sm:border-[1px] border-b-light-grey max-sm:border-light-grey outline-none"><div class="flex flex-row justify-center w-min"><input aria-autocomplete="both" aria-labelledby="autocomplete-165-label" id="autocomplete-165-input" autoComplete="off" autoCorrect="off" autoCapitalize="off" enterKeyHint="search" spellcheck="false" maxLength="512" type="text" class="border-b outline-none p-0 max-sm:border-none max-sm:w-screen max-sm:h-full max-sm:!px-[5vw] max-sm:!py-[16px]" value=""/></div></div></div></div></div></form></div></div><button aria-label="Open menu" type="button" class="HamButton_root__yT8Rh ml-[65px] max-md:ml-[32px] max-sm:ml-[16px]" data-testid="hamburger"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" width="28" height="24" class="HamButton_icon__snr8j" role="img" aria-hidden="true" data-testid="icon-Hamburger"><rect width="100%" height="1"></rect><rect y="10.5" width="100%" height="1"></rect><rect y="21" width="100%" height="1"></rect></svg></button><div><div class="fixed inset-0 z-[100]" style="background:rgba(0, 0, 0, 0);visibility:hidden"><div class="relative max-w-[1920px] mx-auto"><aside class="absolute right-0 z-50 w-[500px] max-sm:w-screen h-screen bg-white text-dark-grey" style="opacity:0;box-shadow:-5px -1px 14px 0px rgba(0, 0, 0, 0);transform:translateX(100%) translateZ(0)"></aside></div></div></div></header><main><h1 class="sr-only">Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology</h1><div data-sb-field-path="sections"><section data-section-position="0" data-sb-field-path="sections.0" data-section-name="# Decades of Leadership in Oncology

" data-exclude-from-nav="true" class="BannerCTA_root__Y1b7h BannerCTA_rootM__Ao8DE text-white"><div class="BannerCTA_contentWrapper__k0vCs"><div class="Container_root__KEMgE BannerCTA_content__eJClf"><div class="BannerCTA_titleWrapper__I20w3"><div class="Markdown_root__yL_qp"><h2 class="MarkdownTitle_root__u5rUW BannerCTA_title__2tOVW" id="Decades of Leadership in Oncology" data-sb-field-path=".title">Decades of Leadership in Oncology</h2></div></div><a data-sb-field-path=".button" __metadata="[object Object]" type="Action" class="Action_root__5eDXn Action_secondary__bhUYe Action_large__0Lt9m BannerCTA_button__y1_Xu" role="button" href="/science/"><span class="Action_label__uURx3">Explore Our Approach</span></a></div></div><div class="BannerCTA_mediaContainer__gEYRx"><div class="BannerCTA_mediaFixedWrapper__wYSCW"><div class="BannerCTA_mediaScalingWrapper__dQTQQ"><div class="VideoBlock_root___2PCs BackgroundMedia_root__RH1BM BackgroundMedia_rootBackgroundVideoBlock__v62Ts VideoBlock_rootIsBackground__SmdrO VideoBlock_rootAspectRatio_16_9__zTaA9" data-sb-field-path=".media.0 .media.0.elementId#@id"><video class="VideoBlock_videoContainer__N_0ZZ NativeVideoEmbed_root__3xA9T" autoplay="" muted="" playsinline="" tabindex="-1" disablepictureinpicture=""><source src="https://assets-dam.takeda.com/video/upload/f_auto:video/q_auto/Takeda%20Oncology/Takeda_Oncology_Hero_Banner_Video-science-16x9-large_w7geah_uvhqpr" type="video/mp4" data-sb-field-path=".url#@src"/></video></div></div></div></div><div class="BannerCTA_overlay__2FkXI bg-black" style="opacity:50%"></div></section><section data-section-position="1" data-sb-field-path="sections.1" data-section-name="## Oncology News

" data-exclude-from-nav="false" class="global-pt global-pb global-mt global-mb !pt-10 !pl-0 !pb-10 !pr-0 bg-white SectionWrapperWithTitle_root__CxgEB"><div class="Container_root__KEMgE SectionWrapperWithTitle_container__fUhBZ"><header class="SectionTitleContainer_root__FUs5_ text-dark-grey SectionWrapperWithTitle_sectionTitleContainer__c43Eh" data-testid="sectionTitleContainer"><div class="Markdown_root__yL_qp"><h2 id="Oncology News" class="SectionWrapperWithTitle_title__DOcx1" data-sb-field-path=".title">Oncology News</h2></div></header><div class="mt-[-36px] SectionWrapperWithTitle_titleLinkContainer__NGrFb"><a __metadata="[object Object]" type="Link" data-sb-field-path=".link" class="inline-flex items-center hover:text-primary-active SectionWrapperWithTitle_titleLink__nFvZT" role="link" aria-label="View All" href="/news/news-releases/"><span class="">View All</span></a></div><div class="Container_root__KEMgE NewsroomTextTopicsSection_container__2xx0I"><div class="NewsroomTextTopicsSection_topicWrapper__zerg9 border-medium-grey"><article class="NewsroomTextTopicsSection_topic__s9Bp6"><a class="NewsroomTextTopicsSection_topicLink__9JKlR" role="link" href="/news/news-releases/positive-topline-results-from-verify-study/"><h3 class="NewsroomTextTopicsSection_topicLinkTitle__LO_HM">Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera</h3></a><div class="NewsroomTextTopicsSection_topicDate__YraFf"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomTextTopicsSection_topicDateIcon__y0w9w" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg><span class="NewsroomTextTopicsSection_topicDateText__TfDx8">March 3, 2025</span></div></article></div><div class="NewsroomTextTopicsSection_topicWrapper__zerg9 border-medium-grey"><article class="NewsroomTextTopicsSection_topic__s9Bp6"><a class="NewsroomTextTopicsSection_topicLink__9JKlR" role="link" href="/news/news-releases/elritercept-licensing-agreement/"><h3 class="NewsroomTextTopicsSection_topicLinkTitle__LO_HM">Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics</h3></a><div class="NewsroomTextTopicsSection_topicDate__YraFf"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomTextTopicsSection_topicDateIcon__y0w9w" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg><span class="NewsroomTextTopicsSection_topicDateText__TfDx8">December 3, 2024</span></div></article></div><div class="NewsroomTextTopicsSection_topicWrapper__zerg9 border-medium-grey"><article class="NewsroomTextTopicsSection_topic__s9Bp6"><a class="NewsroomTextTopicsSection_topicLink__9JKlR" role="link" href="/news/news-releases/american-society-of-hematology-ash/"><h3 class="NewsroomTextTopicsSection_topicLinkTitle__LO_HM">Takeda to Showcase Latest Research at the 66th American Society of Hematology (ASH) Annual Meeting</h3></a><div class="NewsroomTextTopicsSection_topicDate__YraFf"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomTextTopicsSection_topicDateIcon__y0w9w" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg><span class="NewsroomTextTopicsSection_topicDateText__TfDx8">November 25, 2024</span></div></article></div><div class="NewsroomTextTopicsSection_topicWrapper__zerg9 border-medium-grey"><article class="NewsroomTextTopicsSection_topic__s9Bp6"><a class="NewsroomTextTopicsSection_topicLink__9JKlR" role="link" href="/news/news-releases/approval-for-fruzaqla-in-japan/"><h3 class="NewsroomTextTopicsSection_topicLinkTitle__LO_HM">Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer</h3></a><div class="NewsroomTextTopicsSection_topicDate__YraFf"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomTextTopicsSection_topicDateIcon__y0w9w" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg><span class="NewsroomTextTopicsSection_topicDateText__TfDx8">September 24, 2024</span></div></article></div></div></div></section><section data-section-position="2" data-sb-field-path="sections.2" data-section-name="Pipeline" data-exclude-from-nav="false" class="BannerCTA_root__Y1b7h BannerCTA_rootM__Ao8DE text-white"><div class="BannerCTA_contentWrapper__k0vCs"><div class="Container_root__KEMgE BannerCTA_content__eJClf"><div class="BannerCTA_titleWrapper__I20w3"><div class="Markdown_root__yL_qp"><div class="BannerCTA_title__2tOVW" data-sb-field-path=".title"><h2 class="MarkdownTitle_root__u5rUW" id="Oncology Pipeline">Oncology Pipeline</h2><p>Discovering and developing innovative therapies to deliver potentially transformative treatments</p></div></div></div><a data-sb-field-path=".button" __metadata="[object Object]" type="Action" class="Action_root__5eDXn Action_secondary__bhUYe Action_large__0Lt9m BannerCTA_button__y1_Xu" role="button" href="/science/pipeline/"><span class="Action_label__uURx3">Explore Pipeline</span></a></div></div><div class="BannerCTA_mediaContainer__gEYRx"><div class="BannerCTA_mediaFixedWrapper__wYSCW"><div class="BannerCTA_mediaScalingWrapper__dQTQQ"><div class="ImageBlock_root__xPYXG BackgroundMedia_imageBlockContainer__8LQLr" style="aspect-ratio:16/9"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".media.0.url" alt="pipeline" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr BackgroundMedia_root__RH1BM BackgroundMedia_rootImageBlock__ohHlx" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAVFBMVEXtwsG1ICHktrOpaWjuxsXUmZXDami4X17Oh4Psv7/apqDSkIqyVlTps7Lgm5nLdHPGUVKlKymTYmGYVVStYFynXlzAeHStSkiSNjXmr62lEhKmKCfkFZDFAAAAPUlEQVQI1wXBhQHAMAzAMBeTcsf0/5+TgJRS02FeAFof0xjw/ukhzm/BY3PRWK8bm4OqyH5shHLGKuLc+gND3wI6pI8c8wAAAABJRU5ErkJggg==&quot;)"/><noscript><img data-sb-field-path=".media.0.url" alt="pipeline" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr BackgroundMedia_root__RH1BM BackgroundMedia_rootImageBlock__ohHlx" sizes="100vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp"/></noscript></span></div></div></div></div><div class="BannerCTA_overlay__2FkXI bg-black" style="opacity:30%"></div></section><section data-section-position="3" data-sb-field-path="sections.3" data-section-name="Topics" data-exclude-from-nav="false" class="global-pt global-pb global-mt global-mb !pl-0 !pb-10 !pr-0 !pt-10 bg-white TopicsSection_root__rHf3W SectionWrapperWithTitle_root__CxgEB"><div class="Container_root__KEMgE SectionWrapperWithTitle_container__fUhBZ"><header class="SectionTitleContainer_root__FUs5_ text-dark-grey SectionWrapperWithTitle_sectionTitleContainer__c43Eh" data-testid="sectionTitleContainer"><div class="Markdown_root__yL_qp"><h2 id="About Takeda Oncology" class="SectionWrapperWithTitle_title__DOcx1" data-sb-field-path=".title">About Takeda Oncology</h2></div></header><div data-sb-field-path=".items" class="TopicsSection_grid__KcnCE"><div class="Grid_grid__AHEYI" style="grid-template-columns:repeat(auto-fill, minmax(max(250px, 30%), 1fr))"><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".0" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1.7777777777777777"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="science" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAeFBMVEWqVUbAnImqkHy6XUylhoF4W0jivJ+/oKDEcl+bbFbsv53DmHqTXk2XTD6bVUm+cV19Y1ORbmqSQjSfUEGrYlW5a1myg3LIrZazk4DDkYyvXkmhhm+Ba0/MloXXppbklIXTkHfPfHK8tpOmdm+lpHmlkpKlc2ypo475rG6/AAAAQklEQVQIHQXBAwLAMAAEsCtWc7bx/x8ugYuLMOvQtQ30LraD1baPSNSoEQg8Y6aEVUB4LhQTUaX39stIXErt3vNOP3pNA7GtpK9sAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="science" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" role="button" href="/science/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="microscope icon" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAMAAAC67D+PAAAANlBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCqLmgCFAAAAEnRSTlMAX0VRjhknaX6HBp1yeAtwM1vgR6nAAAAAQklEQVQIHR3BhwHAIAwDMAcy2fz/bGkkJOXSkCSiKxLJnUhSZW+kwxTc8Fvk5guAVD3mhEdjOPeKp8wRxlEAuCXHB1TDAcUhxD/7AAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="microscope icon" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/microscope_2_kbr2ef 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/microscope_2_kbr2ef 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/microscope_2_kbr2ef 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/microscope_2_kbr2ef 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/microscope_2_kbr2ef 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/microscope_2_kbr2ef 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/microscope_2_kbr2ef 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/microscope_2_kbr2ef 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/microscope_2_kbr2ef 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/microscope_2_kbr2ef 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/microscope_2_kbr2ef 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/microscope_2_kbr2ef"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Science</h5></div></a></div></div><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".1" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1.7777777777777777"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="Oncology medicine" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAe1BMVEXGw8b18++9uoHa3bna2JS+q6fRw8Tq6ePd19W0nJ7UzcXX0K7u5JOurbTVtqrfoW3Fo6HJvL3RyZrJrpPfq6fCnInRz7rsysXYyYDIs7Pao53nu7PEzX/mz8HGqpTDsaW/m2zEuLShsra5sqHfx3Xp26Di0Kyov8fn1nmMvikoAAAAQklEQVQI1wXBhQHAIAADsOIOc3f//8IlgJS91Qi5AYQw+7rMMYNSDWN0SymiHWs6cWePF9VQdt5/1xlAiHIFvx+tf27KA7zeuU1FAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="Oncology medicine" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" role="button" href="/medicines/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="altText of the image" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAJ1BMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCqNwrDBAAAADXRSTlMAYjdnDH5KV3IeJj+Pn5i0WwAAAENJREFUCNdjYODqSGBgYHCV3AQkKxncGRg4BRiUGBiYxVwMGBi0uVrNVBgMuKJNcxgKmFoDZRhM2BQYmBkmihcKigEA+/oI1qJ/5zIAAAAASUVORK5CYII=&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="altText of the image" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/medicine_2_hnvdeo 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/medicine_2_hnvdeo 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/medicine_2_hnvdeo 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/medicine_2_hnvdeo 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/medicine_2_hnvdeo 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/medicine_2_hnvdeo 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/medicine_2_hnvdeo 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/medicine_2_hnvdeo 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/medicine_2_hnvdeo 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/medicine_2_hnvdeo 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/medicine_2_hnvdeo 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/medicine_2_hnvdeo"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Medicines</h5></div></a></div></div><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".2" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1.5000866100814134"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAHCAMAAAAGcixRAAAAV1BMVEX9+/bQrI1UODLNs5bn2cn69evctI/+/v79/frq1ryEal758OP8+O/47dnz4cjUvqSviHfozqq9trHZ0cr07+ju59vbt6XOpn+df2+TV0e6nH95VUlZPDerJqYSAAAARElEQVQIHQXBBQLAIAwAsUNbbDDX/79zCSoiqusCqIjEMOwGFdT4494DpUI3/sqJlKbJnT1/njm1EqPL1tMC1Tzjte4HXlAClCL2vE0AAAAASUVORK5CYII=&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" role="button" href="/patients/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="patient" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAJFBMVEXhJCpHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrEQGB4AAAADHRSTlNLAC8EYFQUDGwie2dSOExpAAAARElEQVQI12MQVGU3NmYQY07wVGUQc/VgFGAQWqwVnsAgyNpWEs5QwOKgNJGBTUyNYSIDu/AKV0OGDsGiRYIMEQwsOwUBN48LkvcnkywAAAAASUVORK5CYII=&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="patient" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/examination_kzjiz6 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/examination_kzjiz6 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/examination_kzjiz6 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/examination_kzjiz6 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/examination_kzjiz6 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/examination_kzjiz6 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/examination_kzjiz6 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/examination_kzjiz6 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/examination_kzjiz6 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/examination_kzjiz6 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/examination_kzjiz6 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/examination_kzjiz6"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Patients</h5></div></a></div></div><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".3" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1.7777777777777777"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="Man in business suit" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEVfUz/Hsaathnb59uzNysXg4trt2MFgX1fGurbT0cieloPEqpqMbnqypq6sopSSdV26w8E7MSpWW1ahpKKJgXSpqKBTT0qwc1bbxrqOkY9eWFPd4eTz7+Xl1s9/bU/Qv7GIa1OnqbKHd2LAmYbj3tCah3pjY1tEY2a7AAAAQUlEQVQI1wXBhQGAMAADsM7dcHf4/0QSCCI4mZmxgOzlQFeWNqBJsZ3G5bgsCkpXqdvtJz68StXUBY+c+RO10cH/bKUDhkRDHEYAAAAASUVORK5CYII=&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="Man in business suit" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" target="_blank" role="button" rel="noreferrer" href="https://www.takeda.com/investors/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="bar chart" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAIVBMVEXhJCpHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCoMImqYAAAAC3RSTlMvAE1VJ0JeOBkPaexQlEEAAAA6SURBVAjXYxAUFJR0ZACS0xaByElgUtiCQbBZXc2CQUK1nMmFYVKQWbILg0OqUrALQ+niNKtQBjAAAEHHCx2KQWOBAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="bar chart" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/bars_jdlvhq 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/bars_jdlvhq 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/bars_jdlvhq 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/bars_jdlvhq 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/bars_jdlvhq 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/bars_jdlvhq 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/bars_jdlvhq 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/bars_jdlvhq 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/bars_jdlvhq 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/bars_jdlvhq 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/bars_jdlvhq 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/bars_jdlvhq"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Investors</h5></div></a></div></div><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".4" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:16/9"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEXa3MeSiHtugIdviKB2kZqJlpKqnJSsq6dvf5aSkoydp6lXP0Wwv8WqpqHJwsGgsbjs6NrEurZ0lqGPfXdheHrBs6fBr6hNTUhqXVK6p6Glr62TmJTq6s6Rh5jj48d+lKGhqbXTz8iysqXDw72FioqCdHS+vbtEmgfUAAAAQklEQVQIHQXBhQGAMAADsM5dcIeh/59IgkZOfRVzBkBkp75wX+uOkRilvA0ABmGWJyV/vmipmO1BS3TgNdeMab25H3dcA30EaLpFAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" role="button" href="/partnerships/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="handshake icon" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAIVBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCo9B3drAAAAC3RSTlMAJ1toChJHO1N8MVSpe/0AAAA3SURBVAjXY2AAA1YgDmAQ0qoSUmRIF0oJLGTQCEpLbWKQMHIQVmRgsTQ0dmBgcJ6ZAFIbwgAFAO2/B9Tajn2XAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="handshake icon" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/handshake_jpvdgf 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/handshake_jpvdgf 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/handshake_jpvdgf 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/handshake_jpvdgf 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/handshake_jpvdgf 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/handshake_jpvdgf 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/handshake_jpvdgf 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/handshake_jpvdgf 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/handshake_jpvdgf 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/handshake_jpvdgf 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/handshake_jpvdgf 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/handshake_jpvdgf"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Partnerships</h5></div></a></div></div><div class="Grid_gridItemWrapper___t_uD"><div data-sb-field-path=".5" class="ImageWithLink_root__d2u2x"><div class="ImageWithLink_imageContainer__UU46L"><div class="ImageWithLink_imageOuterWrapper__GZhWp"><div class="ImageWithLink_imageInnerWrapper__hap2j"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:4/3"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover;background-size:cover;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEX9++u6pJRSVE63rZiHfW+bhneTlYP6+fPf2ML19Nx8SzZVOjfZ1MzJtJ1hUz9xTTXLuqzw7+bYzMSymYzSxsKQeGri5MyScl+Gb2qZd2NoMCGukoWfdFre2tW0jnNZOyrt6tD08uazmH/UwLXBvruFgoV5YlDdifmZAAAARElEQVQIHQXBhQHAIBAEsIMCj1N3obr/iE1QAkSNFLoHAypqO64MPqPvrWZCGcQc/OvZMC2I4eLu2Vc7otCnPFKys/sBYdIDdEgDooIAAAAASUVORK5CYII=&quot;)"/><noscript><img data-sb-field-path=".image.url" alt="altText of the image" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_image__Y_mUP" sizes="(max-width: 572px) 80vw, (max-width: 886px) 40vw, 25vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_128/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord"/></noscript></span></div></div></div></div><a data-sb-field-path=".titleUrl#@href" class="" role="button" href="/about/careers/"><div class="ImageWithLink_titleWrapper__LTIbY ImageWithLink_titleWrapperClickable__aAecS bg-light-grey"><div class="ImageWithLink_iconImageWrapper__vl6Y_"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:1"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".icon.url" alt="goal icon" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain;background-size:contain;background-position:0% 0%;filter:blur(20px);background-image:url(&quot;data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAMFBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCr59l8uAAAAEHRSTlMACAJvU3wXXGdBJThOiy6j25XIHQAAAD5JREFUCNdjYGBg2GIIJISmA0mmiigFIPtoG5Bgct8GJBltTRYwMLDFN05gYEi+5ziBIbvLaeEEhvA7MSFGAEvzDhWK5bmKAAAAAElFTkSuQmCC&quot;)"/><noscript><img data-sb-field-path=".icon.url" alt="goal icon" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:contain" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr ImageWithLink_iconImage__TUGm3" sizes="10vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_48/v1/Takeda%20Oncology/goal_s13vo4 48w, https://assets-dam.takeda.com/image/upload/c_lfill,w_64/v1/Takeda%20Oncology/goal_s13vo4 64w, https://assets-dam.takeda.com/image/upload/c_lfill,w_96/v1/Takeda%20Oncology/goal_s13vo4 96w, https://assets-dam.takeda.com/image/upload/c_lfill,w_128/v1/Takeda%20Oncology/goal_s13vo4 128w, https://assets-dam.takeda.com/image/upload/c_lfill,w_256/v1/Takeda%20Oncology/goal_s13vo4 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/v1/Takeda%20Oncology/goal_s13vo4 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/Takeda%20Oncology/goal_s13vo4 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/Takeda%20Oncology/goal_s13vo4 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/Takeda%20Oncology/goal_s13vo4 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/Takeda%20Oncology/goal_s13vo4 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/goal_s13vo4 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/Takeda%20Oncology/goal_s13vo4"/></noscript></span></div></div><h5 data-sb-field-path=".title" class="ImageWithLink_title__JNjTu">Oncology Careers</h5></div></a></div></div></div></div></div></section><section data-section-position="4" data-sb-field-path="sections.4" data-section-name="# Divider Section" data-exclude-from-nav="true" class="global-pt global-pb global-mt global-mb bg-white"><div class="Container_root__KEMgE DividerSectionDefault_container__sbOI_"><hr data-sb-field-path=".divider" class="Divider_root____wNZ bg-light-grey"/></div></section><section data-section-position="5" data-sb-field-path="sections.5" data-section-name="# Our Viewpoints

" data-exclude-from-nav="true" class="global-pt global-pb global-mt global-mb bg-white NewsroomHotNewsSection_root__BgoGy SectionWrapperWithTitle_root__CxgEB"><div class="Container_root__KEMgE SectionWrapperWithTitle_container__fUhBZ"><header class="SectionTitleContainer_root__FUs5_ text-dark-grey SectionWrapperWithTitle_sectionTitleContainer__c43Eh" data-testid="sectionTitleContainer"><div class="Markdown_root__yL_qp"><h2 class="MarkdownTitle_root__u5rUW SectionWrapperWithTitle_title__DOcx1" id="Our Viewpoints" data-sb-field-path=".title">Our Viewpoints</h2></div></header><div class="mt-[-36px] SectionWrapperWithTitle_titleLinkContainer__NGrFb"><a __metadata="[object Object]" type="Link" data-sb-field-path=".link" class="inline-flex items-center hover:text-primary-active SectionWrapperWithTitle_titleLink__nFvZT" role="link" aria-label="View all" href="/news/our-viewpoints/"><span class="">View all</span></a></div><div class="NewsroomHotNewsSection_articles__6fQdk"><div class="NewsroomHotNewsSection_mainColumn__ezKvS"><article class="NewsroomHotNewsItem_root__7OvIO NewsroomHotNewsItem_rootMainItem__4QTyJ NewsroomHotNewsSection_articleMainItem__yFLyr"><a class="NewsroomHotNewsItem_imageLink__uh1WK" role="link" href="/news/our-viewpoints/living-is-more-than-surviving/"><div class="ImageBlock_root__xPYXG NewsroomHotNewsItem_imageBlock__tQa2A" style="aspect-ratio:16/9"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr NewsroomHotNewsItem_image__MH0CV" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover"/><noscript><img alt="Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr NewsroomHotNewsItem_image__MH0CV" sizes="(max-width: 697px) 100vw, 60vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More"/></noscript></span></div></a><div class="NewsroomHotNewsItem_textInfo__D6T99"><div class="NewsroomHotNewsItem_meta__u8Gfr"><span class="NewsroomHotNewsItem_publishDate__5i6D4"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomHotNewsItem_icon__chB49" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg>May 29, 2024</span><span class="NewsroomHotNewsItem_delimiter__8F4IG">|</span><span class="NewsroomHotNewsItem_taxonomy__ulMVk">Patients</span></div><h3 class="NewsroomHotNewsItem_title__kH_K0"><a tabindex="0" class="NewsroomHotNewsItem_titleLink__u_8ln" role="link" href="/news/our-viewpoints/living-is-more-than-surviving/">Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact</a></h3><p class="NewsroomHotNewsItem_description__RQ_Jf">Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology  Leadership  Article</p></div></article></div><div class="NewsroomHotNewsSection_column__nuyhP"><article class="NewsroomHotNewsItem_root__7OvIO NewsroomHotNewsSection_articleItem__3O62s"><a class="NewsroomHotNewsItem_imageLink__uh1WK" role="link" href="/news/our-viewpoints/beyond-early-detection-bridging-the-gaps-in-metastatic-colorectal-cancer-support/"><div class="ImageBlock_root__xPYXG NewsroomHotNewsItem_imageBlock__tQa2A" style="aspect-ratio:16/9"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img alt="Beyond Early Detection: Bridging the Gaps in Metastatic Colorectal Cancer Support" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr NewsroomHotNewsItem_image__MH0CV" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover"/><noscript><img alt="Beyond Early Detection: Bridging the Gaps in Metastatic Colorectal Cancer Support" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU ImageBlock_imageGlobalBorderRadius__1CbDr NewsroomHotNewsItem_image__MH0CV" sizes="(max-width: 697px) 100vw, 40vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_256/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 256w, https://assets-dam.takeda.com/image/upload/c_lfill,w_384/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 384w, https://assets-dam.takeda.com/image/upload/c_lfill,w_480/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/q_auto:eco/f_auto/v1/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection"/></noscript></span></div></a><div class="NewsroomHotNewsItem_textInfo__D6T99"><div class="NewsroomHotNewsItem_meta__u8Gfr"><span class="NewsroomHotNewsItem_publishDate__5i6D4"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomHotNewsItem_icon__chB49" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg>February 29, 2024</span></div><h3 class="NewsroomHotNewsItem_title__kH_K0"><a tabindex="0" class="NewsroomHotNewsItem_titleLink__u_8ln" role="link" href="/news/our-viewpoints/beyond-early-detection-bridging-the-gaps-in-metastatic-colorectal-cancer-support/">Beyond Early Detection: Bridging the Gaps in Metastatic Colorectal Cancer Support</a></h3></div></article><article class="NewsroomHotNewsItem_root__7OvIO NewsroomHotNewsSection_articleItem__3O62s"><div class="NewsroomHotNewsItem_textInfo__D6T99"><div class="NewsroomHotNewsItem_meta__u8Gfr"><span class="NewsroomHotNewsItem_publishDate__5i6D4"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomHotNewsItem_icon__chB49" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg>January 30, 2024</span></div><h3 class="NewsroomHotNewsItem_title__kH_K0"><a tabindex="0" class="NewsroomHotNewsItem_titleLink__u_8ln" role="link" href="/news/our-viewpoints/embracing-AI-emerging-technologies-to-advance-cancer-care/"> Embracing AI &amp; Emerging Technologies to Advance Cancer Care</a></h3></div></article><article class="NewsroomHotNewsItem_root__7OvIO NewsroomHotNewsSection_articleItem__3O62s"><div class="NewsroomHotNewsItem_textInfo__D6T99"><div class="NewsroomHotNewsItem_meta__u8Gfr"><span class="NewsroomHotNewsItem_publishDate__5i6D4"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 25 24" class="NewsroomHotNewsItem_icon__chB49" role="img" aria-hidden="false" data-testid="icon-Calendar"><title>Calendar</title><path d="M 9.375 11.052631578947368 L 9.375 9.473684210526315 L 10.9375 9.473684210526315 L 10.9375 11.052631578947368 L 9.375 11.052631578947368 Z M 14.0625 20.526315789473685 L 14.0625 18.94736842105263 L 15.625 18.94736842105263 L 15.625 20.526315789473685 L 14.0625 20.526315789473685 Z M 18.75 11.052631578947368 L 18.75 9.473684210526315 L 20.3125 9.473684210526315 L 20.3125 11.052631578947368 L 18.75 11.052631578947368 Z M 14.0625 11.052631578947368 L 14.0625 9.473684210526315 L 15.625 9.473684210526315 L 15.625 11.052631578947368 L 14.0625 11.052631578947368 Z M 9.375 14.210526315789473 L 9.375 12.631578947368421 L 10.9375 12.631578947368421 L 10.9375 14.210526315789473 L 9.375 14.210526315789473 Z M 4.6875 14.210526315789473 L 4.6875 12.631578947368421 L 6.25 12.631578947368421 L 6.25 14.210526315789473 L 4.6875 14.210526315789473 Z M 18.75 14.210526315789473 L 18.75 12.631578947368421 L 20.3125 12.631578947368421 L 20.3125 14.210526315789473 L 18.75 14.210526315789473 Z M 14.0625 14.210526315789473 L 14.0625 12.631578947368421 L 15.625 12.631578947368421 L 15.625 14.210526315789473 L 14.0625 14.210526315789473 Z M 9.375 17.36842105263158 L 9.375 15.789473684210527 L 10.9375 15.789473684210527 L 10.9375 17.36842105263158 L 9.375 17.36842105263158 Z M 4.6875 17.36842105263158 L 4.6875 15.789473684210527 L 6.25 15.789473684210527 L 6.25 17.36842105263158 L 4.6875 17.36842105263158 Z M 18.75 17.36842105263158 L 18.75 15.789473684210527 L 20.3125 15.789473684210527 L 20.3125 17.36842105263158 L 18.75 17.36842105263158 Z M 14.0625 17.36842105263158 L 14.0625 15.789473684210527 L 15.625 15.789473684210527 L 15.625 17.36842105263158 L 14.0625 17.36842105263158 Z M 9.375 20.526315789473685 L 9.375 18.94736842105263 L 10.9375 18.94736842105263 L 10.9375 20.526315789473685 L 9.375 20.526315789473685 Z M 4.6875 20.526315789473685 L 4.6875 18.94736842105263 L 6.25 18.94736842105263 L 6.25 20.526315789473685 L 4.6875 20.526315789473685 Z M 20.3125 1.5789473684210527 L 25 1.5789473684210527 L 25 23.684210526315788 L 0 23.684210526315788 L 0 1.5789473684210527 L 4.6875 1.5789473684210527 L 4.6875 0 L 6.25 0 L 6.25 2 L 18.75 2 L 18.75 0 L 20.3125 0 L 20.3125 1.5789473684210527 Z M 4.6875 3.1578947368421053 L 1.5625 3.1578947368421053 L 1.5625 6.315789473684211 L 23.4375 6.315789473684211 L 23.4375 3.1578947368421053 L 20.3125 3.1578947368421053 L 20.3125 4.7368421052631575 L 18.75 4.7368421052631575 L 18.75 3.1578947368421053 L 6.25 3.1578947368421053 L 6.25 4.7368421052631575 L 4.6875 4.7368421052631575 L 4.6875 3.1578947368421053 Z M 2 22 L 23 22 L 23 8 L 2 8 L 2 22 Z"></path></svg>August 15, 2023</span></div><h3 class="NewsroomHotNewsItem_title__kH_K0"><a tabindex="0" class="NewsroomHotNewsItem_titleLink__u_8ln" role="link" href="/news/our-viewpoints/cancer-treatment-is-more-than-medicine/">Cancer Treatment is More Than Medicine</a></h3></div></article></div></div></div></section></div></main><footer data-sb-field-path="IV5sQe0KJfPcurPYxLZQeL:footer" class="Footer_footer__FLo8i"><div class="Footer_wrapper__8NTjf"><div class="flex items-center max-lg:flex-col max-lg:items-start"><a class="Footer_logo__5v4_H" role="link" href="/"><div class="ImageBlock_root__xPYXG" style="aspect-ratio:2.8125"><span style="box-sizing:border-box;display:block;overflow:hidden;width:initial;height:initial;background:none;opacity:1;border:0;margin:0;padding:0;position:absolute;top:0;left:0;bottom:0;right:0"><img data-sb-field-path=".logo.url" alt="altText of the image" __metadata="[object Object]" src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" decoding="async" data-nimg="fill" class="ImageBlock_image__2_PsU rounded-none" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover"/><noscript><img data-sb-field-path=".logo.url" alt="altText of the image" __metadata="[object Object]" loading="lazy" decoding="async" data-nimg="fill" style="position:absolute;top:0;left:0;bottom:0;right:0;box-sizing:border-box;padding:0;border:none;margin:auto;display:block;width:0;height:0;min-width:100%;max-width:100%;min-height:100%;max-height:100%;object-fit:cover" class="ImageBlock_image__2_PsU rounded-none" sizes="100vw" srcSet="https://assets-dam.takeda.com/image/upload/c_lfill,w_480/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257 480w, https://assets-dam.takeda.com/image/upload/c_lfill,w_640/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257 640w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1080/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257 1080w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1200/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257 1200w, https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257 1920w" src="https://assets-dam.takeda.com/image/upload/c_lfill,w_1920/v1/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257"/></noscript></span></div></a><ul class="flex items-center ml-auto max-lg:ml-0 max-lg:mt-[24px]" data-sb-field-path="IV5sQe0KJfPcurPYxLZQeL:footer.socialLinks"><li class="flex mr-[24px] max-xs:mr-[16px] last:mr-0" data-sb-field-path=".0"><a elementId="" __metadata="[object Object]" type="Social" class="group link Social_root__o_eDx SocialDefault_root__q7_ra" target="_blank" role="link" aria-label="Instagram" rel="noreferrer" href="http://www.instagram.com/TakedaOncology"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 24 24" class="Social_icon__VzKdr SocialDefault_icon__TItH1" role="img" aria-hidden="false" __metadata="[object Object]" type="Icon" data-testid="icon-Instagram"><title>Instagram</title><path d="M12 0c-3.26 0-3.667 0.015-4.947 0.072-1.278 0.060-2.148 0.261-2.913 0.558-0.789 0.306-1.459 0.717-2.126 1.384s-1.079 1.336-1.384 2.126c-0.297 0.765-0.499 1.635-0.558 2.913-0.060 1.28-0.072 1.687-0.072 4.947s0.015 3.667 0.072 4.947c0.060 1.277 0.261 2.148 0.558 2.913 0.306 0.788 0.717 1.459 1.384 2.126s1.336 1.079 2.126 1.384c0.766 0.296 1.636 0.499 2.913 0.558 1.28 0.060 1.687 0.072 4.947 0.072s3.667-0.015 4.947-0.072c1.277-0.060 2.148-0.262 2.913-0.558 0.788-0.306 1.459-0.718 2.126-1.384 0.666-0.667 1.079-1.335 1.384-2.126 0.296-0.765 0.499-1.636 0.558-2.913 0.060-1.28 0.072-1.687 0.072-4.947s-0.015-3.667-0.072-4.947c-0.060-1.277-0.262-2.149-0.558-2.913-0.306-0.789-0.718-1.459-1.384-2.126-0.667-0.667-1.335-1.079-2.126-1.384-0.765-0.297-1.636-0.499-2.913-0.558-1.28-0.060-1.687-0.072-4.947-0.072zM12 2.16c3.203 0 3.585 0.016 4.85 0.071 1.17 0.055 1.805 0.249 2.227 0.415 0.562 0.217 0.96 0.477 1.382 0.896 0.419 0.42 0.679 0.819 0.896 1.381 0.164 0.422 0.36 1.057 0.413 2.227 0.057 1.266 0.070 1.646 0.070 4.85s-0.015 3.585-0.074 4.85c-0.061 1.17-0.256 1.805-0.421 2.227-0.224 0.562-0.479 0.96-0.899 1.382-0.419 0.419-0.824 0.679-1.38 0.896-0.42 0.164-1.065 0.36-2.235 0.413-1.274 0.057-1.649 0.070-4.859 0.070-3.211 0-3.586-0.015-4.859-0.074-1.171-0.061-1.816-0.256-2.236-0.421-0.569-0.224-0.96-0.479-1.379-0.899-0.421-0.419-0.69-0.824-0.9-1.38-0.165-0.42-0.359-1.065-0.42-2.235-0.045-1.26-0.061-1.649-0.061-4.844 0-3.196 0.016-3.586 0.061-4.861 0.061-1.17 0.255-1.814 0.42-2.234 0.21-0.57 0.479-0.96 0.9-1.381 0.419-0.419 0.81-0.689 1.379-0.898 0.42-0.166 1.051-0.361 2.221-0.421 1.275-0.045 1.65-0.060 4.859-0.060l0.045 0.030zM12 5.838c-3.405 0-6.162 2.76-6.162 6.162 0 3.405 2.76 6.162 6.162 6.162 3.405 0 6.162-2.76 6.162-6.162 0-3.405-2.76-6.162-6.162-6.162zM12 16c-2.21 0-4-1.79-4-4s1.79-4 4-4 4 1.79 4 4-1.79 4-4 4zM19.846 5.595c0 0.795-0.646 1.44-1.44 1.44-0.795 0-1.44-0.646-1.44-1.44s0.646-1.439 1.44-1.439c0.793-0.001 1.44 0.645 1.44 1.439z"></path></svg></a></li><li class="flex mr-[24px] max-xs:mr-[16px] last:mr-0" data-sb-field-path=".1"><a elementId="" __metadata="[object Object]" type="Social" class="group link Social_root__o_eDx SocialDefault_root__q7_ra" target="_blank" role="link" aria-label="facebook" rel="noreferrer" href="https://facebook.com/takedaoncology"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 24 24" class="Social_icon__VzKdr SocialDefault_icon__TItH1" role="img" aria-hidden="false" __metadata="[object Object]" type="Icon" data-testid="icon-Facebook"><title>Facebook</title><path d="M24 12.073c0-6.627-5.373-12-12-12s-12 5.373-12 12c0 5.99 4.388 10.954 10.125 11.854v-8.385h-3.047v-3.47h3.047v-2.642c0-3.007 1.792-4.669 4.533-4.669 1.312 0 2.686 0.235 2.686 0.235v2.953h-1.514c-1.491 0-1.956 0.925-1.956 1.874v2.25h3.328l-0.532 3.47h-2.796v8.385c5.738-0.901 10.126-5.866 10.126-11.855z"></path></svg></a></li><li class="flex mr-[24px] max-xs:mr-[16px] last:mr-0" data-sb-field-path=".2"><a elementId="" __metadata="[object Object]" type="Social" class="group link Social_root__o_eDx SocialDefault_root__q7_ra" target="_blank" role="link" aria-label="Twitter" rel="noreferrer" href="https://twitter.com/takedaoncology"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 1200 1227" class="Social_icon__VzKdr SocialDefault_icon__TItH1" role="img" aria-hidden="false" __metadata="[object Object]" type="Icon" data-testid="icon-Twitter"><title>X</title><path d="M714.163 519.284L1160.89 0H1055.03L667.137 450.887L357.328 0H0L468.492 681.821L0 1226.37H105.866L515.491 750.218L842.672 1226.37H1200L714.137 519.284H714.163ZM569.165 687.828L521.697 619.934L144.011 79.6944H306.615L611.412 515.685L658.88 583.579L1055.08 1150.3H892.476L569.165 687.854V687.828Z"></path></svg></a></li><li class="flex mr-[24px] max-xs:mr-[16px] last:mr-0" data-sb-field-path=".3"><a elementId="" __metadata="[object Object]" type="Social" class="group link Social_root__o_eDx SocialDefault_root__q7_ra" target="_blank" role="link" aria-label="LinkedIn" rel="noreferrer" href="https://www.linkedin.com/company/takedaoncology"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 22 21" class="Social_icon__VzKdr SocialDefault_icon__TItH1" role="img" aria-hidden="false" __metadata="[object Object]" type="Icon" data-testid="icon-LinkedIn"><title>LinkedIn</title><path d="M 0.24739583333333331 6.173705722070846 L 4.544270833333333 6.173705722070846 L 4.544270833333333 19 L 0.24739583333333331 19 L 0.24739583333333331 6.173705722070846 Z M 4.153645833333333 0.627724795640327 C 4.587673611111112 1.0462079927338777 4.809027777777779 1.5747048138056288 4.817708333333333 2.2132152588555862 C 4.826388888888889 2.8430971843778368 4.607204861111112 3.3694368755676645 4.16015625 3.7922343324250676 C 3.713107638888889 4.2150317892824685 3.125 4.4264305177111725 2.3958333333333335 4.4264305177111725 L 2.3697916666666665 4.4264305177111725 C 1.6579861111111114 4.4264305177111725 1.0850694444444446 4.2150317892824685 0.6510416666666667 3.7922343324250676 C 0.21701388888888884 3.3694368755676645 0 2.8430971843778368 0 2.2132152588555862 C 0 1.5747048138056288 0.22352430555555552 1.0462079927338777 0.6705729166666667 0.627724795640327 C 1.117621527777778 0.20924159854677427 1.7013888888888893 0 2.421875 0 C 3.142361111111111 0 3.719618055555556 0.20924159854677427 4.153645833333333 0.627724795640327 Z M 18.645833333333332 7.345027247956403 C 19.54861111111111 8.32436421435059 20 9.758855585831062 20 11.648501362397822 L 20 19 L 15.716145833333332 19 L 15.716145833333332 12.140326975476839 C 15.716145833333332 11.23433242506812 15.540364583333332 10.524636693914623 15.188802083333332 10.011239782016348 C 14.837239583333332 9.497842870118072 14.288194444444446 9.241144414168938 13.541666666666668 9.241144414168938 C 12.994791666666668 9.241144414168938 12.53689236111111 9.389986376021797 12.16796875 9.68767029972752 C 11.799045138888891 9.985354223433243 11.5234375 10.354223433242508 11.341145833333332 10.794277929155314 C 11.245659722222223 11.053133514986376 11.197916666666668 11.40258855585831 11.197916666666668 11.842643051771118 L 11.197916666666668 19 L 6.9140625 19 C 6.931423611111112 15.557220708446865 6.940104166666666 12.76589464123524 6.940104166666666 10.626021798365123 C 6.940104166666666 8.486148955495004 6.935763888888889 7.209128065395094 6.927083333333334 6.794959128065395 L 6.9140625 6.173705722070846 L 11.197916666666668 6.173705722070846 L 11.197916666666668 8.037465940054496 L 11.171875 8.037465940054496 C 11.34548611111111 7.761353315168028 11.5234375 7.51975476839237 11.705729166666668 7.312670299727522 C 11.888020833333332 7.105585831062671 12.133246527777779 6.881244323342415 12.44140625 6.639645776566757 C 12.749565972222223 6.398047229791097 13.127170138888891 6.210376930063577 13.57421875 6.076634877384197 C 14.021267361111114 5.942892824704814 14.518229166666668 5.876021798365122 15.065104166666668 5.876021798365122 C 16.549479166666668 5.876021798365122 17.743055555555557 6.365690281562215 18.645833333333332 7.345027247956403 Z"></path></svg></a></li></ul></div></div><div class="Footer_footerNavigationWrapper__s8_1L"><div class="flex max-md:flex-col"><div></div></div></div><div class="mt-[72px] max-md:mt-[48px] font-sans px-[40px] max-sm:px-[20px] pb-8"><div class="Markdown_root__yL_qp"><div class="text-[16px] max-md:text-[14px] max-sm:text-[14x]" data-sb-field-path="IV5sQe0KJfPcurPYxLZQeL:footer.copyrightText"><p>All trademarks are the property of their respective owners.</p><p>2025 Takeda Pharmaceuticals U.S.A., Inc.</p><p>All rights reserved. 01/23</p></div></div></div></footer><div class="BackToTopButton_root__UWnGG BackToTopButton_rootHidden__n18ZW"><button aria-label="Back to top" class="BackToTopButton_button__k2dGB" style="transform:scale(0) translateZ(0)"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" fill="currentColor" viewBox="0 0 512 512" class="BackToTopButton_icon__w_yny" role="img" aria-hidden="false" data-testid="icon-BackToTop"><title>Back to top</title><path d="m512 256c0 141.386719-114.613281 256-256 256s-256-114.613281-256-256 114.613281-256 256-256 256 114.613281 256 256zm0 0"></path><g fill="white"><path d="m335.183594 184.558594-79.183594-79.183594-79.183594 79.183594 22.625 22.625 40.558594-40.558594v121.136719h32v-121.136719l40.558594 40.558594zm0 0"></path><path d="m240 319.761719h32v32h-32zm0 0"></path><path d="m240 383.761719h32v32h-32zm0 0"></path></g></svg></button></div></div></div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"page":{"disableScrollRestoration":false,"metaTitle":"Takeda Oncology: Decades of Leadership in Oncology | Takeda Oncology","isBackToTopBtnEnabled":true,"enablePageNavigation":false,"headerPosition":"sticky","sections":[{"titleColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"excludeFromNavigation":true,"title":"# Decades of Leadership in Oncology\n\n","overlayColor":{"color":"black","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"overlayOpacity":50,"displayName":"","media":[{"url":"https://assets-dam.takeda.com/video/upload/v1676668648/Takeda%20Oncology/Takeda_Oncology_Hero_Banner_Video-science-16x9-large_w7geah_uvhqpr.mp4","elementId":"","loop":false,"__metadata":{"modelName":"BackgroundVideoBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"BackgroundVideoBlock"}],"button":{"url":"/science/","size":"large","style":"secondary","label":"Explore Our Approach","__metadata":{"modelName":"Action","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Action"},"hideTitle":false,"elementId":"","heightVariants":"50%","__metadata":{"modelName":"BannerCTA","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"BannerCTA"},{"title":"## Oncology News\n\n","excludeFromNavigation":false,"titleColor":{"color":"dark-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"dividerColor":{"color":"medium-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"displayName":"","elementId":"","hideTitle":false,"padding":{"top":"10","left":"0","bottom":"10","right":"0"},"count":4,"viewAllLink":{"url":"/news/news-releases/","label":"View All","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},"filterByTaxonomy":[{"displayName":"News Releases","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"77D45030-95BA-4467-B89F-3AE0BFEF908B","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"Taxonomy"}],"backgroundColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"__metadata":{"modelName":"NewsroomTextTopicsSection","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"NewsroomTextTopicsSection","articles":[{"slug":"/news/news-releases/positive-topline-results-from-verify-study","publishDate":"2025-03-03T17:22:00.000Z","visibleInListings":true,"content":"*   **Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo**\n*   **All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes**\n*   **Rusfertide was generally well tolerated; no new safety findings were observed in the study**\n\n**NEWARK, California, OSAKA, Japan and CAMBRIDGE, Massachusetts, March 3, 2025**  Protagonist Therapeutics, Inc. (Protagonist) ([NASDAQ:PTGX](https://www.protagonist-inc.com/)) and Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/overview/)) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first-in-class investigational hepcidin mimetic peptide therapeutic, which has received Orphan Drug designation and Fast Track designation from the U.S. Food \u0026 Drug Administration (FDA).\n\nKey findings from the study include:\n\n*   The primary endpoint of the study was met, with a significantly higher proportion of clinical responders\u003csup\u003e1\u003c/sup\u003e among rusfertide-treated patients with PV (77%) compared to those who received placebo (33%) during weeks 20-32; p\u003c0.0001. The primary endpoint of the study was the proportion of patients achieving a response, which was defined as the absence of phlebotomy eligibility.\n*   The first key secondary endpoint, which is the pre-specified primary endpoint for European Union (EU) regulators, was also met, with a mean of 0.5 phlebotomies per patient in the rusfertide arm compared to 1.8 phlebotomies per patient in the placebo arm during weeks 0-32; p\u003c0.0001.\n*   The other three pre-specified key secondary endpoints, namely hematocrit control\u003csup\u003e2\u003c/sup\u003e and patient-reported outcomes using PROMIS Fatigue SF-8a\u003csup\u003e3\u003c/sup\u003e and MFSAF TSS-7\u003csup\u003e4\u003c/sup\u003e, were also achieved with statistical significance.\n*   Rusfertide was generally well tolerated in the Phase 3 VERIFY trial, and safety was in line with previous rusfertide clinical studies. No new safety findings were observed in the study. The majority of adverse events were grade 1-2 injection site reactions and all serious adverse events reported were deemed to be not drug related. There was no evidence of an increased risk of cancer in rusfertide-treated patients compared to those on placebo.\n\nThe positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class erythrocytosis-specific agent to address unmet medical needs in patients with PV who are unable to achieve adequate hematocrit control despite standard of care treatments, said Arturo Molina, M.D., M.S., Chief Medical Officer of Protagonist. We plan to submit additional details of these promising results for presentation at upcoming medical conferences in 2025. We are immensely grateful to the patients, study staff and principal investigators who made the VERIFY study possible.\n\nPatients with PV are at increased risk for life-threatening cardiovascular and thrombotic events. Many patients with PV require regular phlebotomy, a process of removing blood to manage elevated hematocrit levels caused by an excess of red blood cells, as well as treatment with cytoreductive therapies. Phlebotomy can be burdensome and exacerbate symptoms, including severe fatigue, visual disturbances and iron deficiency, which impact patients quality of life. The reduction of hematocrit below 45% is a primary treatment goal for patients with PV as recommended by current treatment guidelines.\n\nWe are encouraged by these results and excited about the potential of rusfertide to help patients living with PV. These patients may experience a high treatment burden, and severe symptoms can impact their quality of life, said Andy Plump, M.D., Ph.D., President of R\\\u0026D at Takeda. We are deeply committed to bringing additional treatment options to those living with blood cancers, including myeloid cancers such as PV.\n\nThe totality of impressive clinical data to date shows that rusfertide has the potential for meaningful positive impact on the lives of patients with PV, said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. We look forward to working with our partner, Takeda, to submit our findings to the regulatory agencies. Todays study results also mark a critical inflection point in Protagonists decade long journey in the hepcidin program and further validates our platform and expertise in innovating highly differentiated peptide-based medicines to fulfill unmet medical needs.\n\nUnder the license and collaboration agreement between Protagonist and Takeda, Protagonist earns a $25 million milestone payment following these positive results. The milestone is payable following completion of the VERIFY clinical study report.\n\nThe impact on Takedas financial results for the fiscal year ending March 31, 2025 (FY2024), following the study results, is immaterial.\n\nProtagonist will host a conference call and webcast, for which details can be found below.\n\n## Protagonist Investor Conference Call and Webcast Details\n\nThe dial-in numbers for Protagonists investor update on Monday, March 3rd at 8:30 am ET are:\n\n*   US-based Investors: 1-877-300-8521\n*   International Investors: 1-412-317-6026\n*   Conference Call ID: 1793905\n\nThe webcast link for the event can be found here: \u003chttps://viavid.webcasts.com/starthere.jsp?ei=1708360\u0026tp_key=94f2832555\u003e\n\nA replay of the presentation will be available on the Protagonist Investor Relations Events and Presentations webpage following the event.\n\n## About VERIFY\n\nThe Phase 3 VERIFY trial (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The trial is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy dependent despite standard of care treatment, which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study was the proportion of patients achieving a response during weeks 20-32, which was defined as the absence of phlebotomy eligibility. To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit 45% that was 3% higher than their baseline hematocrit value, or hematocrit 48%.\n\nAll patients have completed their participation in the randomized, placebo-controlled portion of the trial evaluating the efficacy and safety of rusfertide plus current treatment versus placebo plus current treatment and are now in the open-label portions of the trial.\n\n## About Protagonist\n\nProtagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (IL-23R) which is licensed to JNJ Innovative Medicines (JNJ), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.\n\nMore information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at [www.protagonist-inc.com](https://www.protagonist-inc.com/).\n\n## About Takeda\n\nTakeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\\\u0026D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](www.takeda.com).\n\n## Protagonist Cautionary Note on Forward-Looking Statements\n\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of rusfertide and the timing of rusfertide clinical trial data and regulatory submission. In some cases, you can identify these statements by forward-looking words such as \"anticipate,\" \"believe,\" \"may,\" \"will,\" \"expect,\" or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading \"Risk Factors\" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.\n\n## Takeda Important Notice\n\nFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.\n\nThe companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.\n\n## Takeda Forward-Looking Statements\n\nThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could, anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: \u003chttps://www.takeda.com/investors/sec-filings-and-security-reports/\u003e or at [www.sec.gov](www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.\n\n## Takeda Medical Information\n\nThis press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.\n\n## Protagonist Investor Relations Contact\n\n**Corey Davis, Ph.D.**\n\nLifeSci Advisors\n\n+1 212 915 2577\n\n\u003ccdavis@lifesciadvisors.com\u003e\n\n## Protagonist Media Contact\n\n**Virginia Amann, Founder/CEO**\n\nENTENTE Network of Companies\n\n+1 833 500 0061 ext 1\n\n\u003cvirginiaamann@ententeinc.com\u003e\n\n## Takeda Media Contacts:\n\n**Japanese Media**\n\nTsuyoshi Tada\n\n\u003ctsuyoshi.tada@takeda.com\u003e\n\n**U.S. and International Media**\n\nEmy Gruppo\n\n\u003cemy.gruppo@takeda.com\u003e\n","description":"Explore efficacy and safety results from the Phase 3 VERIFY study evaluating Protagonist and Takeda's rusfertide in patients with polycythemia vera.","title":"Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera","taxonomies":[{"displayName":"News Releases","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"77D45030-95BA-4467-B89F-3AE0BFEF908B","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"Taxonomy"}],"__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"419fa48b-af33-4305-9c24-579e660c5a32","createdAt":"2025-02-26T17:21:20Z","updatedAt":"2025-03-03T11:50:41Z"},"type":"Article","featuredImg":{"access_mode":"public","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","type":"cloudinary.asset","format":"svg","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","bytes":3685,"width":1080,"uploaded_by":{"id":"553579438111562","type":"accesskey"},"height":599,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2023-01-31T18:17:13Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}}},{"publishDate":"2024-12-03T14:00:00.000Z","visibleInListings":true,"taxonomies":[{"displayName":"News Releases","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"77D45030-95BA-4467-B89F-3AE0BFEF908B","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"Taxonomy"}],"slug":"/news/news-releases/elritercept-licensing-agreement","content":"*\t***Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis***\n*\t***Takeda to receive exclusive global license in all territories outside of mainland China, Hong Kong and Macau***\n*\t***Transaction builds upon Takedas legacy in the treatment of hematologic cancers and advances companys global oncology strategy***\n\n**OSAKA, Japan and CAMBRIDGE, Massachusetts, December 3, 2024**  Takeda ([TSE:4502/NYSE:TAK](https://www.takeda.com/investors/overview/)) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau. \n\nElritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes (MDS) and myelofibrosis (MF). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for very low-, low- and intermediate-risk MDS. MDS and MF are characterized by inadequate blood cell production, often leading to severe anemia that significantly impacts patient health and quality of life. Elritercept targets activin A and B proteins, which are believed to play a crucial role in anemia-associated diseases. In early clinical studies, elritercept has shown promising clinical activity and a manageable safety profile in patients with very low-, low- and intermediate-risk MDS as a monotherapy and in patients with MF in combination with standard of care.\n\nElritercept has the potential to make a meaningful difference for patients with blood cancers, one of our key areas of strategic focus, said Teresa Bitetti, President of the Global Oncology Business Unit at Takeda. The addition of elritercept further bolsters our oncology pipeline and introduces a potential future growth driver for Takeda. I am excited to further advance the pioneering work begun by the Keros Therapeutics team with the goal of delivering this potential treatment option to patients. \n\nElritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. Takeda plans to evaluate elritercept in these cancers across patient segments and lines of therapy.\n\nWe are excited to partner with Takeda, whose global reach and expertise in oncology and hematology will help unlock elritercepts potential for patients with MDS and MF, said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer at Keros Therapeutics. With a differentiated mechanism of action targeting a broad range of pathways in blood cell production, elritercept has shown promise for patients who have not responded to standard therapies. This collaboration will accelerate development of elritercept for patients in need and offer new insights into these complex hematologic conditions.\n\nUnder the terms of the agreement, Takeda will receive an exclusive worldwide license to further develop, manufacture and commercialize elritercept in all indications and territories outside of mainland China, Hong Kong and Macau. Takeda will be responsible for all development, manufacturing and commercialization as of the effective date of the agreement. Takeda will provide Keros Therapeutics with an upfront payment of $200 million and potential payments relating to regulatory, development and commercial sales milestones, as well as royalties on net sales. The agreement is subject to customary closing conditions, including completion of antitrust reviews.\n\n## About  Myelodysplastic Syndromes (MDS)\nMyelodysplastic syndromes (MDS) are a group of diverse blood cancers in which the bone marrow fails to produce enough healthy blood cells. MDS is among the most common hematologic malignancies, with approximately 20,000 new cases diagnosed annually in the United States.\u003csup\u003e1\u003c/sup\u003e Most people with MDS experience anemia, or low red blood cell counts, which impacts quality of life and mortality.\u003csup\u003e2\u003c/sup\u003e 75% of people living with MDS have low-risk MDS, with a median survival of approximately three to 10 years.\u003csup\u003e3,4\u003c/sup\u003e Many low-risk MDS patients require frequent red blood cell transfusions, which can increase over time and negatively impact quality of life.\u003csup\u003e5\u003c/sup\u003e Despite advances, additional therapeutic options are needed to improve quality of life and anemia symptoms for patients with low-risk MDS, particularly those whose disease is ringed sideroblast-negative or who have a high transfusion need.\n\n## About  Myelofibrosis (MF)\nMyelofibrosis (MF) is a rare and life-threatening blood cancer characterized by the buildup of scar tissue in the bone marrow, which impairs its ability to produce normal blood cells. In the United States, approximately 3,000 new cases of MF are diagnosed each year.\u003csup\u003e6\u003c/sup\u003e Patients with MF often experience anemia, enlarged spleen and other symptoms that significantly affect their quality of life. Although standard treatments can reduce spleen size and improve symptoms, they may exacerbate anemia and lead to low platelet counts. \n\n## About  Elritercept\nElritercept is an investigational, potentially best-in-class activin inhibitor, targeting both activin A and activin B proteins, which are believed to play a crucial role in anemia-associated diseases. Elritercept is currently in two ongoing Phase 2 clinical trials; one in patients with very low-, low- or intermediate-risk MDS and one in patients with MF. The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk MDS will begin enrollment soon. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of elritercept for this condition. \n\n## About  Takeda\nTakeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\u0026D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](https://www.takeda.com/).\n\n### Media Contacts:\n\n#### Japanese Media\n\nTsuyoshi Tada\n\n[tsuyoshi.tada@takeda.com](mailto:tsuyoshi.tada@takeda.com)\n\n#### U.S. and International Media\n\nJennifer Anderson\n\n[jennifer.anderson@takeda.com](mailto:jennifer.anderson@takeda.com)\n\n## Important Notice\nFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.\n\nThe companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.\n\n## Forward-Looking Statements \nThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could, anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](https://www.takeda.com/investors/sec-filings-and-security-reports/) or at [www.sec.gov](https://www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.\n\n## Medical Information\nThis press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.\n\n## References:  \n1.\tGorak E, et al. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies. Blood Adv. 2023 Oct 24;7(20):6120-6129. doi: 10.1182/bloodadvances.2023010061.\n2.\tHaring Y, et al. MDS-Related Anemia Is Associated with Impaired Quality of Life but Improvement Is Not Always Achieved by Increased Hemoglobin Level. J Clin Med. 2023 Sep 9;12(18):5865. doi: 10.3390/jcm12185865.\n3.\tde Witte T, et al. Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome: The European LeukemiaNet MDS Registry and MDS-RIGHT project perspective. Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817.\n4.\tSekeres M, et al. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578.\n5.\tWood E, et al. Outpatient transfusions for myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):167-174. doi: 10.1182/hematology.2020000103.\n6.\tMehta J, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014 Mar;55(3):595-600.  doi: 10.3109/10428194.2013.813500. Epub 2013 Jul 29.\n\n\n\n\n","description":"Takeda to secure rights to elritercept, a treatment for anemia in hematologic cancers, enhancing their oncology pipeline.","title":"Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics","__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"35e5cc7e-aa67-48c6-ac67-3ce96e6c02e1","createdAt":"2024-12-03T02:57:32Z","updatedAt":"2024-12-03T11:55:12Z"},"type":"Article","featuredImg":{"access_mode":"public","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","type":"cloudinary.asset","format":"svg","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","bytes":3685,"width":1080,"uploaded_by":{"id":"553579438111562","type":"accesskey"},"height":599,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2023-01-31T18:17:13Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}}},{"title":"Takeda to Showcase Latest Research at the 66th American Society of Hematology (ASH) Annual Meeting","slug":"/news/news-releases/american-society-of-hematology-ash","taxonomies":[{"displayName":"News Releases","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"77D45030-95BA-4467-B89F-3AE0BFEF908B","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"Taxonomy"}],"publishDate":"2024-11-25T18:32:00.000Z","description":"Discover Takeda's research findings at ASH 2024, highlighting treatments for leukemia, lymphoma, and rare blood disorders.","visibleInListings":true,"content":"* Notable Presentations Highlight Promising Treatment Advancements for Patients with Chronic Myeloid Leukemia, Hodgkin Lymphoma and Polycythemia Vera\n \n**OSAKA, Japan and CAMBRIDGE, Massachusetts, November 25, 2024 ** Takeda [(TSE:4502/NYSE:TAK](https://www.takeda.com/investors/overview/)) will present data showcasing the latest advancements across its diverse portfolio and pipeline at the 66th American Society of Hematology (ASH) Annual Meeting being held December 7-10, 2024, in San Diego, California. The presentations demonstrate Takedas commitment to advancing treatment options and help improve outcomes for people living with hematological diseases and blood cancers.\n\nThe presentations will include five-year follow-up of the Phase 2 OPTIC study providing updated long-term efficacy and safety data of ICLUSIG (ponatinib) in patients with chronic-phase (CP) chronic myeloid leukemia (CML) who were resistant or intolerant to at least two prior tyrosine kinase inhibitors (TKIs) or had T315I-positive CML. Results from two post-hoc analyses from the Phase 3 PhALLCON trial evaluating ICLUSIG versus imatinib plus reduced-intensity chemotherapy will also be presented, providing additional data for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Additionally, four presentations evaluating data from the Phase 3 HD21 study will be featured, including the German Hodgkin Study Groups (GHSG) oral presentation of results from a single-arm cohort evaluating ADCETRIS (brentuximab vedotin) with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (BrECADD) in elderly patients with advanced-stage Hodgkin lymphoma.  \n\nThe data we are sharing enhances our understanding of Takedas approved therapies and how they may advance care and outcomes for specific patient populations, said Phuong Khanh (PK) Morrow, M.D., head of the oncology therapeutic area unit at Takeda. Our expertise in developing small molecules, antibody-drug conjugates and other innovative cancer modalities has been instrumental in driving this research forward and will continue to guide our strategic focus as a company dedicated to oncology innovation. \n\nAdditional presentations will feature the Phase 2 REVIVE final study results evaluating rusfertide (TAK-121) in polycythemia vera patients, as part of our license and collaboration agreement with Protagonist Therapeutics, Inc., and new Phase 3 data on ADZYNMA (ADAMTS13, recombinant-krhn) in pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP). \n\nOur driving purpose is to inspire hope and unlock new possibilities for patients living with rare blood disorders, said Obi Umeh, M.D., MSc., vice president, franchise global program leader at Takeda. Our commitment to developing innovative therapies has never been stronger, as we work tirelessly to help meet unaddressed needs and elevate patient care. Were excited to present these findings at ASH and shed more light on the progress being made in the treatment of hematologic conditions.  \n\nA full list of company-sponsored abstracts can be found [here](https://assets-dam.takeda.com/image/upload/v1732320943/Takeda%20Oncology/News/Congresses/ASH_2024_Abstract.pdf).\n\n## About ICLUSIG (ponatinib) tablets\n\nICLUSIG is a kinase inhibitor targeting BCR::ABL1, an abnormal tyrosine kinase that is expressed in CML and Ph+ ALL. ICLUSIG is a targeted cancer medicine developed using a computational and structure-based drug-design platform, specifically designed to inhibit the activity of BCR::ABL1 and its mutations. ICLUSIG inhibits native BCR::ABL1, as well as all BCR::ABL1 treatment-resistant mutations, including the most resistant T315I mutation. This mutation has been associated with resistance to all other approved TKIs. ICLUSIG received full approval from the FDA in November 2016. ICLUSIG is currently indicated in the U.S. for adult patients with newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). In addition, it is approved as monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL, chronic-phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors, accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated, or T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.\n\n### IMPORTANT SAFETY INFORMATION\n\n\u003cdiv style=\"border: 2px solid black; padding: 10px;\"\u003e\n  \u003cp style=\"text-align: center;\"\u003e\u003cb\u003eWARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY\u003c/b\u003e\u003c/p\u003e\n  \u003cp style=\"text-align: center;\"\u003e\u003cb\u003eSee full prescribing information for complete boxed warning.\u003c/b\u003e\u003c/p\u003e\n  \u003cul\u003e\n    \u003cli\u003e\u003cb\u003eArterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG.\u003c/b\u003e\u003c/li\u003e\n    \u003cli\u003e\u003cb\u003eVenous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity.\u003c/b\u003e\u003c/li\u003e\n    \u003cli\u003e\u003cb\u003eHeart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure.\u003c/b\u003e\u003c/li\u003e\n    \u003cli\u003e\u003cb\u003eHepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on severity.\u003c/b\u003e\u003c/li\u003e\n  \u003c/ul\u003e\n\u003c/div\u003e\n\n \n\u003ch3\u003eWARNINGS AND PRECAUTIONS\u003c/h3\u003e\n\n\u003cp\u003e**Arterial Occlusive Events (AOEs)**: AOEs, including fatalities, have occurred in patients who received ICLUSIG in PhALLCON, OPTIC and PACE. These included cardiovascular, cerebrovascular, and peripheral vascular events. In PhALLCON, 6% of 163 patients experienced AOEs; 3.7% experienced Grade 3 or 4. The incidence of AOEs in OPTIC (45 mg  15 mg) was 14% of 94 patients; 6% experienced Grade 3 or 4. In PACE, the incidence of AOEs was 26% of 449 patients; 14% experienced Grade 3 or 4. Fatal AOEs occurred in 0.6% of patients in PhALLCON, 2.1% of patients in OPTIC, and in 2% of patients in PACE. Some patients in PACE experienced recurrent or multisite vascular occlusion. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. The most common risk factors observed with these events in PACE were history of hypertension, hypercholesterolemia, and non-ischemic cardiac disease. In PhALLCON, OPTIC and PACE, AOEs were more frequent with increasing age.\u003c/p\u003e\n\nIn PhALLCON, patients with uncontrolled hypertension, hypertriglyceridemia, or diabetes were excluded. Patients with clinically significant, uncontrolled, or active cardiovascular disease, including any history of myocardial infarction, peripheral vascular infarction, revascularization procedure, venous thromboembolism, clinically significant atrial/ventricular tachyarrhythmias, unstable angina, or congestive heart failure within the 6 months prior to the first dose of ICLUSIG, were also excluded.\n\nIn OPTIC, patients with uncontrolled hypertension or diabetes and patients with clinically significant, uncontrolled, or active cardiovascular disease were excluded. \n\nIn PACE, patients with uncontrolled hypertriglyceridemia and patients with clinically significant or active cardiovascular disease within the 3 months prior to the first dose of ICLUSIG were excluded. \n\nConsider whether the benefits of ICLUSIG are expected to exceed the risks. Monitor for evidence of AOEs. Interrupt, then resume at the same or decreased dose or discontinue ICLUSIG based on recurrence/severity. Consider benefit-risk to guide a decision to restart ICLUSIG.\n\n**Venous Thromboembolic Events (VTEs):** Serious or severe VTEs have occurred in patients who received ICLUSIG. In PhALLCON, VTEs occurred in 12% of 163 patients, including serious or severe (Grade 3 or 4) in 3.1% of patients.  One of 94 patients in OPTIC experienced a VTE (Grade 1 retinal vein occlusion). In PACE, VTEs occurred in 6% of 449 patients including serious or severe (Grade 3 or 4) VTEs in 5.8% of patients. In PhALLCON and PACE VTEs included deep venous thrombosis, embolism, pulmonary embolism, superficial vein thrombosis, thrombosis, jugular vein thrombosis, superficial thrombophlebitis, retinal vein occlusion, and retinal vein thrombosis with vision loss. The incidence of VTEs in PACE was higher in patients with Ph+ ALL (9% of 32 patients) and BP-CML (10% of 62 patients). Monitor for evidence of VTEs. Interrupt, then resume at the same or decreased dose or discontinue ICLUSIG based on recurrence/severity.\n\n**Heart Failure:** Fatal, serious or severe heart failure events have occurred in patients who received ICLUSIG. In PhALLCON, heart failure occurred in 6% of 163 patients; 1.2% experienced serious or severe (Grade 3 or 4) heart failure. Heart failure occurred in 13% of 94 patients in OPTIC; 1.1% experienced serious or severe (Grade 3 or 4). In PACE, heart failure occurred in 9% of 449 patients; 7% experienced serious or severe (Grade 3 or higher).  In PhALLCON the most frequently reported heart failure event (\u003e1 patient) was increased brain natriuretic peptide (BNP) (2.5%). In OPTIC, the most frequently reported heart failure events (\u003e1 patient each) were left ventricular hypertrophy (3.2%) and BNP increased (3.2%). In PACE, the most frequently reported heart failure events (2%) were congestive cardiac failure (3.1%), decreased ejection fraction (2.9%), and cardiac failure (2%). Monitor patients for signs or symptoms consistent with heart failure and manage heart failure as clinically indicated. Interrupt, then resume at reduced dose or discontinue ICLUSIG for new or worsening heart failure.\n\n**Hepatotoxicity:** ICLUSIG can cause hepatotoxicity, including liver failure and death. Fulminant hepatic failure leading to death occurred in 3 patients, with hepatic failure occurring within 1 week of starting ICLUSIG in one of these patients. These fatal cases occurred in patients with BP-CML or Ph+ ALL treated with monotherapy. Hepatotoxicity occurred in 66% of 163 patients in PhALLCON, in 28% of 94 patients in OPTIC and in 32% of 449 patients in PACE. Grade 3 or 4 hepatotoxicity occurred in PhALLCON (30% of 163 patients), in OPTIC (6% of 94 patients), and in PACE (13% of 449 patients). The most frequent hepatotoxic events were elevations of ALT, AST, GGT, bilirubin, and alkaline phosphatase. Monitor liver function tests at baseline, then at least monthly or as clinically indicated. Interrupt, then resume at a reduced dose or discontinue ICLUSIG based on recurrence/severity.\n\n**Hypertension:** Serious or severe hypertension, including hypertensive crisis, has occurred in patients who received ICLUSIG. Patients may require urgent clinical intervention for hypertension associated with confusion, headache, chest pain, or shortness of breath. Monitor blood pressure at baseline and as clinically indicated and manage hypertension as clinically indicated. Interrupt, dose reduce, or stop ICLUSIG if hypertension is not medically controlled. For significant worsening, labile or treatment-resistant hypertension, interrupt ICLUSIG and consider evaluating for renal artery stenosis.\n\n**Pancreatitis:** Serious or severe pancreatitis has occurred in patients who received ICLUSIG. Elevations of lipase and amylase also occurred. In the majority of cases that led to dose modification or treatment discontinuation, pancreatitis resolved within 2-3 weeks. Monitor serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated. Consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse. Interrupt, then resume at the same or reduced dose or discontinue ICLUSIG based on severity. Evaluate for pancreatitis when lipase elevation is accompanied by abdominal symptoms.\n\n**Increased Toxicity in Newly Diagnosed Chronic Phase CML:** In a prospective randomized clinical trial in the first line treatment of newly diagnosed patients with CP-CML, single agent ICLUSIG 45 mg once daily increased the risk of serious adverse reactions 2-fold compared to single agent imatinib 400 mg once daily. The median exposure to treatment was less than 6 months. The trial was halted for safety. Arterial and venous thrombosis and occlusions occurred at least twice as frequently in the ICLUSIG arm compared to the imatinib arm. Compared to imatinib-treated patients, ICLUSIG-treated patients exhibited a greater incidence of myelosuppression, pancreatitis, hepatotoxicity, cardiac failure, hypertension, and skin and subcutaneous tissue disorders. ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.\n\n**Neuropathy:** Peripheral and cranial neuropathy occurred in patients in PhALLCON, OPTIC and PACE. Some of these events in PhALLCON and PACE were Grade 3 or 4. Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness. Interrupt, then resume at the same or reduced dose or discontinue ICLUSIG based on recurrence/severity.\n\n**Ocular Toxicity:** Serious or severe ocular toxicity leading to blindness or blurred vision have occurred in ICLUSIG-treated patients. The most frequent ocular toxicities occurring in PhALLCON, OPTIC and PACE were dry eye, blurred vision, and eye pain. Retinal toxicities included age-related macular degeneration, macular edema, retinal vein occlusion, retinal hemorrhage, and vitreous floaters. Conduct comprehensive eye exams at baseline and periodically during treatment.\n\n**Hemorrhage:** Fatal and serious hemorrhage events have occurred in patients who received ICLUSIG. Fatal hemorrhages occurred in PACE and serious hemorrhages occurred in PhALLCON, OPTIC and PACE. In PACE, the incidence of serious bleeding events was higher in patients with AP-CML, BP-CML, and Ph+ ALL. Intracranial hemorrhage, gastrointestinal hemorrhage and subdural hematoma were the most frequently reported serious hemorrhages. Events often occurred in patients with Grade 4 thrombocytopenia. Monitor for hemorrhage and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue ICLUSIG based on recurrence/severity.\n\n**Fluid Retention:** Fatal and serious fluid retention events have occurred in patients who received ICLUSIG. In PACE, one instance of brain edema was fatal and serious events included pleural effusion, pericardial effusion, and angioedema. In PhALLCON serious fluid retention included pericardial effusion. The most frequent occurrences of fluid retention in patients who received ICLUSIG were peripheral edema and pleural effusion. Monitor for fluid retention and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue ICLUSIG based on recurrence/severity.\n\n**Cardiac Arrhythmias:** Cardiac arrhythmias, including ventricular, atrial arrhythmias, tachycardia, syncope, atrial fibrillation and supraventricular tachycardia occurred in patients in PhALLCON, OPTIC, and PACE. For some patients, events were serious or severe (Grade 3 or 4) and led to hospitalization. Monitor for signs and symptoms suggestive of slow heart rate (fainting, dizziness) or rapid heart rate (chest pain, palpitations or dizziness) and manage patients as clinically indicated. Interrupt, then resume at the same or reduced dose or discontinue ICLUSIG based on recurrence/severity.\n \n**Myelosuppression:** Grade 3 or 4 events of neutropenia, thrombocytopenia, and anemia occurred in patients in PhALLCON, OPTIC and PACE. In PACE, the incidence of myelosuppression was greater in patients with AP-CML, BP-CML, and Ph+ ALL treated with monotherapy than in patients with CP-CML. Obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated. If ANC less than 1 x 10\u003csup\u003e9\u003c/sup\u003e/L or platelets less than 50 x 10\u003csup\u003e9\u003c/sup\u003e/L, interrupt ICLUSIG until ANC at least 1.5 x 10\u003csup\u003e9\u003c/sup\u003e/L and platelets at least 75 x 10\u003csup\u003e9\u003c/sup\u003e/L, then resume at same or reduced dose.\n\n**Tumor Lysis Syndrome (TLS):** Serious TLS was reported in ICLUSIG-treated patients in PhALLCON, OPTIC and PACE. Ensure adequate hydration and treat high uric acid levels prior to initiating ICLUSIG.\n\n**Reversible Posterior Leukoencephalopathy Syndrome (RPLS):** RPLS (also known as Posterior Reversible Encephalopathy Syndrome) has been reported in patients who received ICLUSIG. Patients may present with neurological signs and symptoms, visual disturbances, and hypertension. Diagnosis is made with supportive findings on magnetic resonance imaging (MRI) of the brain. Interrupt ICLUSIG until resolution. The safety of resumption of ICLUSIG in patients upon resolution of RPLS is unknown.\n\n**Impaired Wound Healing and Gastrointestinal Perforation:** Impaired wound healing occurred in patients receiving ICLUSIG. Withhold ICLUSIG for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of ICLUSIG after resolution of wound healing complications has not been established. Gastrointestinal perforation or fistula occurred in patients receiving ICLUSIG. Permanently discontinue in patients with gastrointestinal perforation.\n\n**Embryo-Fetal Toxicity:** Based on its mechanism of action and findings from animal studies, ICLUSIG can cause fetal harm when administered to a pregnant woman Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with ICLUSIG and for 3 weeks after the last dose.\n\n### ADVERSE REACTIONS\n\nThe most common adverse reactions (occurring in \u003e20% of patients) are:\n\n* ICLUSIG as a single agent: rash and related conditions, arthralgia, abdominal pain, headache, constipation, dry skin, hypertension, fatigue, fluid retention and edema, pyrexia, nausea, pancreatitis/lipase elevation, hemorrhage, anemia, hepatic dysfunction and AOEs. The most common Grade 3 or 4 laboratory abnormalities (\u003e20%) are platelet count decreased, neutrophil cell count decreased, and white blood cell decreased.\n\n* ICLUSIG in combination with chemotherapy: hepatic dysfunction, arthralgia, rash and related conditions, headache, pyrexia, abdominal pain, constipation, fatigue, nausea, oral mucositis, hypertension, pancreatitis/lipase elevation, neuropathy peripheral, hemorrhage, febrile neutropenia, fluid retention and edema, vomiting, paresthesia and cardiac arrhythmias. The most common Grade 3 or 4 laboratory abnormalities (\u003e20%) are decreased white blood cell count, decreased neutrophil cell count, decreased platelet count, decreased lymphocyte cell count, decreased hemoglobin, increased lipase and increased alanine aminotransferase.\n\n \n**To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-817-6468 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program)**.\n\n\u003ch3\u003eDRUG INTERACTIONS\u003c/h3\u003e\n\n**Strong CYP3A Inhibitors:** Avoid coadministration or reduce ICLUSIG dose if coadministration cannot be avoided.\n\n**Strong CYP3A Inducers:** Avoid coadministration.\n \n### USE IN SPECIFIC POPULATIONS\n\n**Lactation:** Advise women not to breastfeed during treatment with ICLUSIG and for 1 week following last dose.\n \n**Females and Males of Reproductive Potential:** Verify pregnancy status of females of reproductive potential prior to initiating ICLUSIG.\nPonatinib may impair fertility in females, and it is not known if these effects are reversible. \n \n**Pre-existing Hepatic Impairment:** For patients with CP-CML, AP-CML, BP-CML, and Ph+ ALL receiving monotherapy, reduce the starting dose of ICLUSIG to 30mg orally once daily for patients with pre-existing hepatic impairment as these patients are more likely to experience adverse reactions compared to patients with normal hepatic function. For patients with newly diagnosed Ph+ ALL, no dosage adjustment is recommended.\n\n[**Prescribing Information**](https://www.iclusig.com/sites/default/files/2023-02/iclusig-prescribing-information.pdf)\n\n## About ADCETRIS (brentuximab vedotin)\n\nADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Pfizers proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.\n\nADCETRIS injection for intravenous infusion has received FDA approval for seven indications: \n\n* Adult patients with previously untreated Stage III/IV classical Hodkin lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine (2018)\n* Pediatric patients 2 years and older with previously untreated high risk cHL in combination with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (2022)\n* Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation (2015)\n* Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates (2011)\n* Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (2018)\n* Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen (2011)\n* Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) after prior systemic therapy (2017)\n\nHealth Canada granted ADCETRIS approval with conditions for relapsed or refractory Hodgkin lymphoma and sALCL in 2013, and non-conditional approval for post-autologous stem cell transplantation (ASCT) consolidation treatment of Hodgkin lymphoma patients at increased risk of relapse or progression in 2017, adults with pcALCL or CD30-expressing MF who have had prior systemic therapy in 2018, for previously untreated Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine in 2019, and for previously untreated adult patients with sALCL, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumors express CD30, in combination with cyclophosphamide, doxorubicin, prednisone in 2019.\n\nADCETRIS received conditional marketing authorization from the European Commission in October 2012, and the specific obligations of the conditional marketing authorization were fulfilled in May 2022. The approved indications in the European Union are: (1) for the treatment of adult patients with previously untreated CD30-positive Stage III \u0026 IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (AVD), (2) for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT, (3) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, (4) for the treatment of adult patients with relapsed or refractory sALCL, (5) for the treatment of adult patients with previously untreated sALCL in combination with CHP and (6) for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.\n\nADCETRIS has received marketing authorization by regulatory authorities in more than 70 countries for relapsed or refractory Hodgkin lymphoma and sALCL. See Important Safety Information below.\n\nADCETRIS is being evaluated broadly in more than 70 clinical trials, including a Phase 3 study in first-line Hodgkin lymphoma (ECHELON-1) and another Phase 3 study in first-line CD30-positive peripheral T-cell lymphomas (ECHELON-2), as well as trials in many additional types of CD30-positive malignancies.\n\nPfizer and Takeda fund joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs. \n\n### ADCETRIS (brentuximab vedotin) Important Safety Information (European Union)\n\nPlease refer to Summary of Product Characteristics (SmPC) before prescribing.\n\n### Contraindications\n\nADCETRIS is contraindicated for patients with hypersensitivity to brentuximab vedotin and its excipients. In addition, combined use of ADCETRIS with bleomycin causes pulmonary toxicity.\n\n### Special Warnings and Precautions\n\n**Progressive multifocal leukoencephalopathy (PML):** John Cunningham virus (JCV) reactivation resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients treated with ADCETRIS. PML has been reported in patients who received ADCETRIS after receiving multiple prior chemotherapy regimens. PML is a rare demyelinating disease of the central nervous system that results from reactivation of latent JCV and is often fatal.\n\nClosely monitor patients for new or worsening neurological, cognitive, or behavioral signs or symptoms, which may be suggestive of PML. Suggested evaluation of PML includes neurology consultation, gadolinium-enhanced magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JCV DNA by polymerase chain reaction or a brain biopsy with evidence of JCV. A negative JCV PCR does not exclude PML. Additional follow-up and evaluation may be warranted if no alternative diagnosis can be established. Hold dosing for any suspected case of PML and permanently discontinue ADCETRIS if a diagnosis of PML is confirmed.\n\nBe alert to PML symptoms that the patient may not notice (e.g., cognitive, neurological, or psychiatric symptoms).\n\n**Pancreatitis:** Acute pancreatitis has been observed in patients treated with ADCETRIS. Fatal outcomes have been reported. Closely monitor patients for new or worsening abdominal pain, which may be suggestive of acute pancreatitis. Patient evaluation may include physical examination, laboratory evaluation for serum amylase and serum lipase, and abdominal imaging, such as ultrasound and other appropriate diagnostic measures. Hold ADCETRIS for any suspected case of acute pancreatitis. ADCETRIS should be discontinued if a diagnosis of acute pancreatitis is confirmed.\n\n**Pulmonary Toxicity:** Cases of pulmonary toxicity, some with fatal outcomes, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), have been reported in patients receiving ADCETRIS. Although a causal association with ADCETRIS has not been established, the risk of pulmonary toxicity cannot be ruled out. Promptly evaluate and treat new or worsening pulmonary symptoms (e.g., cough, dyspnea) appropriately. Consider holding dosing during evaluation and until symptomatic improvement.\n\n**Serious infections and opportunistic infections:** Serious infections such as pneumonia, staphylococcal bacteremia, sepsis/septic shock (including fatal outcomes), and herpes zoster, cytomegalovirus (CMV) (reactivation) and opportunistic infections such as Pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with ADCETRIS. Patients should be carefully monitored during treatment for the emergence of possible serious and opportunistic infections.\n\n**Infusion-related reactions (IRR):** Immediate and delayed IRR, as well as anaphylaxis, have been reported with ADCETRIS. Carefully monitor patients during and after an infusion. If anaphylaxis occurs, immediately and permanently discontinue administration of ADCETRIS and administer appropriate medical therapy. If an IRR occurs, interrupt the infusion and institute appropriate medical management. The infusion may be restarted at a slower rate after symptom resolution. Patients who have experienced a prior IRR should be premedicated for subsequent infusions. IRRs are more frequent and more severe in patients with antibodies to ADCETRIS.\n\n**Tumor lysis syndrome (TLS):** TLS has been reported with ADCETRIS. Patients with rapidly proliferating tumor and high tumor burden are at risk of TLS. Monitor these patients closely and manage according to best medical practice.\n\n**Peripheral neuropathy (PN):** ADCETRIS treatment may cause PN, both sensory and motor. ADCETRIS-induced PN is typically an effect of cumulative exposure to ADCETRIS and is reversible in most cases. Monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay and a dose reduction or discontinuation of ADCETRIS.\n\n**Hematological toxicities:** Grade 3 or Grade 4 anemia, thrombocytopenia, and prolonged (equal to or greater than one week) Grade 3 or Grade 4 neutropenia can occur with ADCETRIS. Monitor complete blood counts prior to administration of each dose.\n\n**Febrile neutropenia:** Febrile neutropenia has been reported with ADCETRIS. Complete blood counts should be monitored prior to administration of each dose of treatment. Closely monitor patients for fever and manage according to best medical practice if febrile neutropenia develops.\n\nWhen ADCETRIS is administered in combination with AVD or CHP, primary prophylaxis with G-CSF is recommended for all patients beginning with the first dose.\n\n**Severe cutaneous adverse reactions (SCARs):** Cases of SCARs, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with ADCETRIS. Fatal outcomes have been reported for SJS and TEN. If SJS, TEN or DRESS occur, ADCETRIS should be discontinued, and appropriate medical therapy should be administered.\n\n**Gastrointestinal (GI) Complications:** GI complications, some with fatal outcomes, including intestinal obstruction, ileus, enterocolitis, neutropenic colitis, erosion, ulcer, perforation and hemorrhage, have been reported with ADCETRIS. Promptly evaluate and treat patients if new or worsening GI symptoms occur.\n\n**Hepatotoxicity:** Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) have been reported with ADCETRIS. Serious cases of hepatotoxicity, including fatal outcomes, have also occurred. Pre-existing liver disease, comorbidities, and concomitant medications may also increase the risk. Test liver function prior to treatment initiation and routinely monitor during treatment. Patients experiencing hepatotoxicity may require a delay, dose modification, or discontinuation of ADCETRIS.\n\n**Hyperglycemia:** Hyperglycemia has been reported during trials in patients with an elevated body mass index (BMI) with or without a history of diabetes mellitus. Closely monitor serum glucose for patients who experience an event of hyperglycemia. Administer anti-diabetic treatment as appropriate.\n\n**Infusion site extravasation:** Extravasation during intravenous infusion has occurred. Given the possibility of extravasation, it is recommended to closely monitor the infusion site for possible infiltration during drug administration.\n\n**Renal and Hepatic Impairment:** There is limited experience in patients with renal and hepatic impairment. Available data indicate that MMAE clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations.\n\n**CD30+ CTCL:** The size of the treatment effect in CD30 + CTCL subtypes other than mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) is not clear due to lack of high level evidence. In two single arm phase II studies of ADCETRIS, disease activity has been shown in the subtypes Szary syndrome (SS), lymphomatoid papulosis (LyP) and mixed CTCL histology. These data suggest that efficacy and safety can be extrapolated to other CTCL CD30+ subtypes. Carefully consider the benefit-risk per patient and use with caution in other CD30+ CTCL patient types.\n\n**Sodium content in excipients:** This medicinal product contains 13.2 mg sodium per vial, equivalent to 0.7% of the WHO recommended maximum daily intake of 2 g sodium for an adult.\n\n**Traceability:** In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.\n\n### INTERACTIONS\n\nPatients who are receiving a strong CYP3A4 and P-gp inhibitor, concomitantly with ADCETRIS may have an increased risk of neutropenia. If neutropenia develops, refer to dosing recommendations for neutropenia (see SmPC section 4.2). Co-administration of ADCETRIS with a CYP3A4 inducer did not alter the plasma exposure of ADCETRIS, but it appeared to reduce plasma concentrations of MMAE metabolites that could be assayed. ADCETRIS is not expected to alter the exposure to drugs that are metabolized by CYP3A4 enzymes.\n\n**PREGNANCY:** Advise women of childbearing potential to use two methods of effective contraception during treatment with ADCETRIS and until 6 months after treatment. There are no data from the use of ADCETRIS in pregnant women, although studies in animals have shown reproductive toxicity. Do not use ADCETRIS during pregnancy unless the benefit to the mother outweighs the potential risks to the fetus.\n\n**LACTATION (breast-feeding):** There are no data as to whether ADCETRIS or its metabolites are excreted in human milk, therefore a risk to the newborn/infant cannot be excluded. A decision should be made whether to discontinue breast-feeding or to discontinue/abstain from this therapy, taking into account a potential risk of breast-feeding for the child and the benefit of therapy for the woman.\n\n**FERTILITY:** In non-clinical studies, brentuximab vedotin treatment has resulted in testicular toxicity, and may alter male fertility. MMAE has been shown to have anagenic properties. Therefore, men being treated with this medicine are advised to have sperm samples frozen and stored before treatment. Men being treated with this medicine are advised not to father a child during treatment and for up to 6 months following the last dose.\n\n**Effects on ability to drive and use machines**: ADCETRIS may have a moderate influence on the ability to drive and use machines.\n\n### UNDESIRABLE EFFECTS\n\n**Monotherapy:** The most frequent adverse reactions (10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhea, pyrexia, upper respiratory tract infection, neutropenia, rash, cough, vomiting, arthralgia, peripheral motor neuropathy, infusion-related reactions, pruritus, constipation, dyspnea, weight decreased, myalgia and abdominal pain. Serious adverse drug reactions occurred in 12% of patients. The frequency of unique serious adverse drug reactions was 1%. Adverse events led to treatment discontinuation in 24% of patients.\n\n**Combination Therapy:** In the studies of ADCETRIS as combination therapy in 662 patients with previously untreated advanced HL (C25003) and 223 patients with previously untreated CD30+ PTCL, the most common adverse reactions ( 10%) were: infections, neutropenia, peripheral sensory neuropathy, nausea, constipation, vomiting, diarrhea, fatigue, pyrexia, alopecia, anemia, weight decreased, stomatitis, febrile neutropenia, abdominal pain, decreased appetite, insomnia, bone pain, rash, cough, dyspnea, arthralgia, myalgia, back pain, peripheral motor neuropathy, upper respiratory tract infection, and dizziness. In patients receiving ADCETRIS combination therapy, serious adverse reactions occurred in 34% of patients. Serious adverse reactions occurring in  3% of patients included febrile neutropenia (15%), pyrexia (5%), and neutropenia (3%). Adverse events led to treatment discontinuation in 10% of patients. \n\n**ADCETRIS (brentuximab vedotin) for injection U.S. Important Safety Information**\n\n**BOXED WARNING**\n\n**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML, and death can occur in ADCETRIS-treated patients.**\n\n### CONTRAINDICATION\n\nContraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).\n\n### WARNINGS AND PRECAUTIONS\n\n**Peripheral neuropathy (PN):** ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.\n\n**Anaphylaxis and infusion reactions:** Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.\n\n**Hematologic toxicities:** Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (1 week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.\n\nAdminister G-CSF primary prophylaxis beginning with Cycle 1 for adult patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL, and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.\n\nMonitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.\n\n**Serious infections and opportunistic infections:** Infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.\n\n**Tumor lysis syndrome:** Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.\n\n**Increased toxicity in the presence of severe renal impairment:** The frequency of Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.\n\n**Increased toxicity in the presence of moderate or severe hepatic impairment:** The frequency of Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.\n\n**Hepatotoxicity:** Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.\n\n**PML:** Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.\n\n**Pulmonary toxicity:** Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.\n\n**Serious dermatologic reactions:** Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.\n\n**Gastrointestinal (GI) complications:** Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with pre-existing GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.\n\n**Hyperglycemia:** Serious cases, such as new-onset hyperglycemia, exacerbation of pre-existing diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.\n\n**Embryo-fetal toxicity:** Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS treatment and for 4 months after the last dose of ADCETRIS.\n\n### ADVERSE REACTIONS\n\nThe most common adverse reactions (20% in any study) are peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, mucositis, thrombocytopenia, and febrile neutropenia.\n\n### DRUG INTERACTIONS\n\nConcomitant use of strong CYP3A4 inhibitors has the potential to affect the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.\n\n### USE IN SPECIAL POPULATIONS\n\n**Lactation:** Breastfeeding is not recommended during ADCETRIS treatment.\n\n**Please see the full Prescribing Information, including BOXED WARNING, for ADCETRIS [here](https://seagendocs.com/Adcetris_Full_Ltr_Master.pdf).** \n\n## About ADZYNMA (ADAMTS13 recombinant-krhn)\n\nADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant A disintegrin and metalloproteinase with thrombospondin motifs 13 ADAMTS13 (rADAMTS13) indicated for prophylactic or on-demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP).\n\n### IMPORTANT SAFETY INFORMATION\n\n**ADZYNMA is contraindicated** in patients who have experienced life-threatening hypersensitivity reactions to ADZYNMA or its components.\n\n**Hypersensitivity Reactions:** Allergic-type hypersensitivity, including anaphylactic reactions, may occur with ADZYNMA. Patients should be educated about early signs of hypersensitivity such as tachycardia, chest tightness, wheezing and/or acute respiratory distress, hypotension, generalized urticaria, pruritus, rhinoconjunctivitis, angioedema, lethargy, nausea, vomiting, paresthesia, and restlessness. If signs and symptoms of severe allergic reactions occur, immediately discontinue administration of ADZYNMA and provide appropriate supportive care.\n\n**Immunogenicity:** There is a potential for immunogenicity with ADZYNMA. Patients may develop neutralizing antibodies to ADAMTS13, which could potentially result in a decreased or lack of response to ADAMTS13. Patients may develop antibodies to host cell proteins which could potentially result in adverse reactions. There are no data on immunogenicity with ADZYNMA or to host cell proteins in previously untreated patients (subjects nave to plasma-based products).\n\n**Adverse Reactions:** The most commonly observed adverse reactions (\u003e5% of subjects) associated with ADZYNMA are headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting.\n\n**Use in Specific Populations:** The safety of ADZYNMA for use during pregnancy has not been established in controlled clinical trials. Limited data are insufficient to inform a drug associated risk of adverse developmental outcomes. There is no information regarding the presence of ADZYNMA in human milk, its effects on milk production, or the breastfed infant.\n\n**To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program).**\n\n**Please see full [Prescribing Information](https://content.takeda.com/?contenttype=PI\u0026product=ADZ\u0026language=ENG\u0026country=USA\u0026documentnumber=1), including information for patients.**\n\n**ADZYNMA is marketed as ADZYNMA (Recombinant ADAMTS13). Please see approved EMA SmPC for Prescribing Information.** \n\n## About Takeda\n\nTakeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\u0026D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit [www.takeda.com](http://www.takeda.com/).\n\n### Media Contacts:\n\n#### Japanese Media\n\nJun Saito \n\n[jun.saito@takeda.com](mailto:jun.saito@takeda.com)\n\n#### U.S. and International Media\n\nLindsey Colegrove\n\n[lindsey.colegrove@takeda.com ](mailto:lindsey.colegrove@takeda.com )\n\nKara Cournoyer\n\n[Kara.cournoyer@takeda.com](mailto:Kara.cournoyer@takeda.com)\n\n## Important Notice\n\nFor the purposes of this notice, press release means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.\n\n## Forward-Looking Statements\n\nThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could, anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: [https://www.takeda.com/investors/sec-filings/](https://www.takeda.com/investors/sec-filings/) or at [www.sec.gov](www.sec.gov). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.\n\n## Medical Information\n\nThis press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.\n\nADZYNMA is a trademark of Takeda Pharmaceuticals International AG. \n","__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"bd83aefe-4dc5-4d50-a869-a86810c9e25b","createdAt":"2024-11-25T21:36:20Z","updatedAt":"2025-03-11T13:10:56Z"},"type":"Article","featuredImg":{"access_mode":"public","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","type":"cloudinary.asset","format":"svg","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","bytes":3685,"width":1080,"uploaded_by":{"id":"553579438111562","type":"accesskey"},"height":599,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2023-01-31T18:17:13Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}}},{"content":"* ***Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial***\n* ***FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in Japan for Metastatic Colorectal Cancer (mCRC) Regardless of Biomarker Status in Over a Decade***\n\n**OSAKA, Japan and CAMBRIDGE, Massachusetts, September 24, 2024**  Takeda [(TSE:4502/NYSE:TAK)](https://www.takeda.com/investors/overview/) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chemotherapy.\n\nThe approval is based primarily on the results of the FRESCO-2 trial, a global Phase 3 clinical trial conducted in the United States, Europe, Japan and Australia. The trial compared FRUZAQLA plus best supportive care (BSC) with placebo plus BSC in patients with previously treated metastatic colorectal cancer (mCRC). The FRESCO-2 trial met all primary and key secondary efficacy endpoints and demonstrated consistent benefits in patients who received FRUZAQLA, regardless of the types of therapy the patients had previously received. FRUZAQLA demonstrated a manageable safety profile in the FRESCO-2 trial, with the incidence of adverse events leading to discontinuation being 21% in the placebo plus BSC arm compared to 20% in the FRUZAQLA plus BSC arm.\u003csup\u003e1\u003c/sup\u003e The data from the FRESCO-2 trial were [published](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00772-9/abstract) in *The Lancet* in June 2023.\n\nDr. Takayuki Yoshino, deputy director of hospital, head, Division for the Promotion of Drug and Diagnostic Development, and chief, Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, who served on the FRESCO-2 study Steering Committee, said, Although the mortality rate of colorectal cancer has been going down in recent years due to early screening and advances in treatment, the 5-year survival rate for metastatic colorectal cancer remains low and new treatment options are much in need. The approval of FRUZAQLA in Japan offers new hope for patients and families of patients with metastatic colorectal cancer, as well as for healthcare personnel involved in colorectal cancer treatment. I feel that it is of great clinical significance.\n\nFor more than a decade, Takeda has been a leader in advancing the treatment of metastatic colorectal cancer in Japan. With this approval of FRUZAQLA, we are able to further support patients living with this debilitating disease, said Teresa Bitetti, president of the Global Oncology Business Unit at Takeda. FRUZAQLA is now approved in the U.S., European Union, Japan and a number of other countries around the world, and we remain committed to bringing this treatment to additional patients with metastatic colorectal cancer around the world who urgently need new therapeutic options.\n\n## About FRUZAQLA (fruquintinib)\n\nFRUZAQLA is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. FRUZAQLA was designed to have enhanced selectivity that limits off-target kinase activity, allowing for drug exposure achieving sustained target inhibition and flexibility for potential use as part of combination therapy.\n\nTakeda has the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside of mainland China, Hong Kong and Macau. FRUZAQLA was approved by the U.S. Food and Drug Administration (FDA) in November 2023 and by the European Commission (EC) in June 2024. Fruquintinib is developed and marketed in China by HUTCHMED. Fruquintinib was approved for marketing by the China National Medical Products Administration (NMPA) in September 2018 and commercially launched in China in November 2018 under the brand name ELUNATE.\n\n### JAPAN IMPORTANT SAFETY INFORMATION\n\nPlease consult the FRUZAQLA (fruquintinib) Japan package insert (J-PI) before prescribing.\n\n**WARNING:** FRUZAQLA should be administered only to patients for whom the use of FRUZAQLA is considered appropriate under the supervision of a physician with sufficient knowledge of and experience in cancer chemotherapy at a medical institution where adequate emergency care can be provided. Prior to treatment initiation, the efficacy and risks should be fully explained to the patient and/or his/her family and informed consent should be obtained; Severe gastrointestinal hemorrhage, including fatal cases, has been reported. Patients should be carefully monitored, and if any abnormalities are observed, administration of FRUZAQLA should be withheld and appropriate measures should be taken. If severe hemorrhage occurs, FRUZAQLA should not be re-administered; Gastrointestinal perforation has been reported with some fatal cases. Patients should be carefully monitored, and if any abnormalities are observed, administration of FRUZAQLA should be withheld and appropriate measures should be taken. If gastrointestinal perforation occurs, FRUZAQLA should not be re-administered.\n\n**CONTRAINDICATIONS:** Patients with a history of hypersensitivity to any of the ingredients of FRUZAQLA.\n\n**IMPORTANT PRECAUTIONS:** Hypertension, including hypertensive crisis, may occur. Blood pressure should be measured prior to the initiation of FRUZAQLA treatment and periodically during this treatment; Proteinuria may occur. Urinary protein should be monitored prior to the initiation of FRUZAQLA treatment and periodically during this treatment; If a surgical procedure is to be performed, patients are recommended to withhold FRUZAQLA before the surgery because wound healing may be delayed. Treatment resumption after the surgical procedure should be determined depending on the patient's condition upon confirmation of adequate wound healing.\n\n**PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS:** **Patients with hypertension:** Hypertension may worsen; **Patients with bleeding diathesis or abnormal coagulation system:** Hemorrhagic events may occur; **Patients with hemorrhage such as gastrointestinal hemorrhage:** Hemorrhage may be enhanced; **Patients with a complication of intra-abdominal inflammation in the gastrointestinal tract, etc.:** Gastrointestinal perforation may occur; **Patients with current or a history of thromboembolism:** Transient ischaemic attack, thrombotic microangiopathy, pulmonary embolism, portal vein thrombosis, deep vein thrombosis, etc. may occur; **Patients with severe hepatic impairment (Child-Pugh Class C):** Since FRUZAQLA is metabolized mainly in the liver, blood concentrations may be increased. There have been no clinical studies conducted in patients with severe hepatic impairment; **Patients with Reproductive Potential:** Women of childbearing potential should be advised to use adequate contraception during treatment with FRUZAQLA and for 2 weeks after the last dose; **Pregnant Women:** FRUZAQLA can be administered to women who are or may be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with this treatment. In a rat embryo-fetal toxicity study, fetal abnormalities and teratogenic effects consisting of fetal external, visceral, and skeletal malformations and visceral and skeletal variations were observed at exposure levels approximately 0.05 times the exposure level (AUC) of FRUZAQLA at the maximum clinical dose (5 mg/day); **Breast-feeding Women:** It is advisable not to breastfeed. FRUZAQLA may pass into breast milk, and infants may experience serious adverse reactions if they are ingested through breast milk; **Pediatric Use:** There have been no clinical studies conducted in pediatric patients.\n\n### ADVERSE REACTIONS:\n\nAny of the adverse reactions listed below may occur. Patients should be closely monitored, and if any such abnormalities are observed, appropriate measures should be taken, including treatment discontinuation. Clinically Significant Adverse Reactions are follows.\n\n**Hypertension:** Hypertension or hypertensive crisis may occur. If an increase in blood pressure is observed, appropriate treatment such as antihypertensive drug administration should be given as necessary, and if necessary, the dose of fruquintinib should be reduced, or fruquintinib administration should be interrupted. If severe or persistent hypertension, or hypertension that cannot be controlled by routine antihypertensive therapy occurs or if a hypertensive crisis occurs, fruquintinib administration should be discontinued; **Skin disorder:** Skin disorder including palmar-plantar erythrodysesthesia syndrome and rash may occur; **Hemorrhage:** Hemorrhage including epistaxis, hematuria, gastrointestinal hemorrhage and hemoptysis may occur. Fatal outcomes have been reported; **Gastrointestinal perforation:** Fatal outcomes have been reported; **Arterial thromboembolic events:** Arterial thromboembolic events including transient ischemic attack and thrombotic microangiopathy may occur; **Venous thromboembolism events:** Venous thromboembolism such as pulmonary embolism, portal vein thrombosis, and deep vein thrombosis may occur; **Posterior reversible encephalopathy syndrome:** If headaches, convulsions, lethargy, confusion, changes in mental function, blindness or other visual disturbances, or neurological impairment are observed, fruquintinib administration should be discontinued, and appropriate measures should be taken, including blood pressure control; **Arterial dissection:** Arterial dissection including aortic dissection may occur.\n\n***For US Prescribing Information:*** https://www.fruzaqla.com/sites/default/files/resources/fruzaqla-prescribing-information.pdf\n\n***For European Union Summary of Product Characteristics:*** https://www.ema.europa.eu/en/medicines/human/EPAR/fruzaqla\n\n\n## About the Phase 3 FRESCO-2 Trial\n\nThe FRESCO-2 study is a multi-regional clinical trial conducted in the U.S., Europe, Japan and Australia investigating FRUZAQLA plus BSC vs placebo plus BSC in patients with previously treated mCRC ([NCT04322539](https://clinicaltrials.gov/study/NCT04322539)). The study met all of its primary and key secondary endpoints, demonstrating that treatment with FRUZAQLA resulted in statistically significant and clinically meaningful improvement in overall survival and progression-free survival. The safety profile of FRUZAQLA in FRESCO-2 was consistent with previously reported fruquintinib monotherapy studies. Results from the study were [presented](https://oncologypro.esmo.org/meeting-resources/esmo-congress-2022/fresco-2-a-global-phase-iii-multiregional-clinical-trial-mrct-evaluating-the-efficacy-and-safety-of-fruquintinib-in-patients-with-refractory-met) at ESMO in September 2022 and subsequently [published](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00772-9/abstract) in *The Lancet* in June 2023.\u003csup\u003e2,1\u003c/sup\u003e\n\n## Takedas Commitment to Colorectal Cancer in Japan\n\nCRC is the most prevalent type of cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023, according to the National Cancer Centers statistics.\u003csup\u003e3\u003c/sup\u003e While early-stage CRC can be surgically resected, mCRC remains an area of high unmet need with patients awaiting new treatment options, given its poor prognosis and limited treatment options.\u003csup\u003e4-8\u003c/sup\u003e For over a decade, we have contributed to the treatment of patients with late-stage CRC who have limited treatment options and to the advancement of personalized treatment through the provision of innovative medicines and the generation of relevant evidence. Moving forward, we will continue our work to treat patients with CRC and address their unmet needs.\n\n## About Takeda\n\nTakeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R\u0026D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.\n\n### Media Contacts:\n\n#### Japanese Media\n\nAkiko Manome\n\n[akiko.manome@takeda.com](mailto:akiko.manome@takeda.com)\n\n#### U.S. and International Media\n\nEmma Nash\n\n[emma.nash@takeda.com](mailto:emma.nash@takeda.com)\n\n## Important Notice\n\nFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.\n\nThe companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.\n\n## Forward-Looking Statements\n\nThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could, anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: [https://www.takeda.com/investors/sec-filings-and-security-reports/](https://www.takeda.com/investors/sec-filings-and-security-reports/) or at [www.sec.gov](https://www.sec.gov/). Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.\n\n## Medical Information\n\nThis press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.\n\n## References:  \n\n1. Dasari NA, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41-53. doi:10.1016/S0140-6736(23)00772-9.\n2. Dasari NA, et al. LBA25  FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann Oncol. 2022 Sep;33(suppl_7): S808-S869. Doi:10.1016/annonc/annonc1089.\n3. Foundation for Promotion of Cancer Research. Cancer Statistics In Japan. Tokyo, Foundation for Promotion of Cancer Research; 2023.\n4. Bando H, et al. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 2023; 20(5)306-322. doi:10.1038/s41575-022-00736-1.\n5. D'Haene N, et al. Clinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience. Oncotarget. 2018;9(29):20761-20768. Published 2018 Apr 17. doi:10.18632/oncotarget.25099.\n6. Venderbosch, et al. Mismatch repair status and braf mutation status in metastatic colorectal cancer patients: A pooled analysis of the Cairo, Cairo2, coin, and Focus Studies. Clinical Cancer Res.,2014; 20(20):53225330. doi:10.1158/1078-0432.ccr-14-0332.\n7. Koopman, M., et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 209;100(2), 266273. doi:10.1038/sj.bjc.6604867.\n8. Ahcene Djaballah S, et al. HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target.Am Soc Clin Oncol Educ Book. 2022;42:1-14. doi:10.1200/EDBK_351354.\n","slug":"/news/news-releases/approval-for-fruzaqla-in-japan","taxonomies":[{"displayName":"News Releases","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"77D45030-95BA-4467-B89F-3AE0BFEF908B","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"Taxonomy"}],"publishDate":"2024-09-24T18:32:00.000Z","title":"Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer","description":"Takeda announces the approval of FRUZAQLA (fruquintinib) by Japan's Ministry of Health, Labour and Welfare for the treatment of unresectable advanced or recurrent colorectal cancer. The approval is based on the successful Phase 3 FRESCO-2 trial.","visibleInListings":true,"__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"755726c3-ae1d-41f9-b624-24da46e9a41a","createdAt":"2024-09-09T18:31:49Z","updatedAt":"2024-09-24T06:56:40Z"},"type":"Article","featuredImg":{"access_mode":"public","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","type":"cloudinary.asset","format":"svg","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","bytes":3685,"width":1080,"uploaded_by":{"id":"553579438111562","type":"accesskey"},"height":599,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2023-01-31T18:17:13Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}}}]},{"overlayOpacity":30,"button":{"style":"secondary","label":"Explore Pipeline","url":"/science/pipeline/","size":"large","__metadata":{"modelName":"Action","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Action"},"hideTitle":false,"heightVariants":"50%","elementId":"","media":[{"priority":false,"url":{"version":1665426460,"height":2700,"url":"http://res.cloudinary.com/takeda/image/upload/v1665426460/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp.jpg","bytes":2380996,"resource_type":"image","format":"jpg","public_id":"Takeda Oncology/New Images from Simo/Oncology-Pipeline-banner_mmkqcp","width":4800,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665426460/Takeda%20Oncology/New%20Images%20from%20Simo/Oncology-Pipeline-banner_mmkqcp.jpg","created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"type":"cloudinary.asset","access_mode":"public","created_at":"2022-10-10T18:27:40Z","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"pipeline","aspectRatio":"16:9","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAVFBMVEXtwsG1ICHktrOpaWjuxsXUmZXDami4X17Oh4Psv7/apqDSkIqyVlTps7Lgm5nLdHPGUVKlKymTYmGYVVStYFynXlzAeHStSkiSNjXmr62lEhKmKCfkFZDFAAAAPUlEQVQI1wXBhQHAMAzAMBeTcsf0/5+TgJRS02FeAFof0xjw/ukhzm/BY3PRWK8bm4OqyH5shHLGKuLc+gND3wI6pI8c8wAAAABJRU5ErkJggg=="}],"title":"# Oncology Pipeline\u0026#xA;\n\nDiscovering and developing innovative therapies to deliver potentially transformative treatments\n","excludeFromNavigation":false,"displayName":"Pipeline","overlayColor":{"color":"black","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"titleColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"__metadata":{"modelName":"BannerCTA","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"BannerCTA"},{"displayName":"Topics","items":[{"titleUrl":"/science/","image":{"elementId":"","altText":"science","aspectRatio":"","priority":false,"url":{"access_mode":"public","created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"type":"cloudinary.asset","created_at":"2022-10-10T20:17:34Z","width":4800,"version":1665433054,"height":2700,"resource_type":"image","public_id":"Takeda Oncology/New Images from Simo/science_bwhhfk","bytes":1972040,"url":"http://res.cloudinary.com/takeda/image/upload/v1665433054/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk.jpg","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"jpg","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665433054/Takeda%20Oncology/New%20Images%20from%20Simo/science_bwhhfk.jpg","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAeFBMVEWqVUbAnImqkHy6XUylhoF4W0jivJ+/oKDEcl+bbFbsv53DmHqTXk2XTD6bVUm+cV19Y1ORbmqSQjSfUEGrYlW5a1myg3LIrZazk4DDkYyvXkmhhm+Ba0/MloXXppbklIXTkHfPfHK8tpOmdm+lpHmlkpKlc2ypo475rG6/AAAAQklEQVQIHQXBAwLAMAAEsCtWc7bx/x8ugYuLMOvQtQ30LraD1baPSNSoEQg8Y6aEVUB4LhQTUaX39stIXErt3vNOP3pNA7GtpK9sAAAAAElFTkSuQmCC"},"icon":{"url":{"uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"resource_type":"image","access_mode":"public","url":"http://res.cloudinary.com/takeda/image/upload/v1663609283/Takeda%20Oncology/microscope_2_kbr2ef.svg","bytes":3465,"created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"version":1663609283,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663609283/Takeda%20Oncology/microscope_2_kbr2ef.svg","created_at":"2022-09-19T17:41:23Z","height":512,"format":"svg","type":"cloudinary.asset","public_id":"Takeda Oncology/microscope_2_kbr2ef","width":512,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"microscope icon","aspectRatio":"","priority":false,"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAMAAAC67D+PAAAANlBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCqLmgCFAAAAEnRSTlMAX0VRjhknaX6HBp1yeAtwM1vgR6nAAAAAQklEQVQIHR3BhwHAIAwDMAcy2fz/bGkkJOXSkCSiKxLJnUhSZW+kwxTc8Fvk5guAVD3mhEdjOPeKp8wRxlEAuCXHB1TDAcUhxD/7AAAAAElFTkSuQmCC"},"title":"Science","__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"},{"icon":{"elementId":"","altText":"altText of the image","aspectRatio":"","priority":false,"url":{"type":"cloudinary.asset","width":512,"resource_type":"image","height":512,"format":"svg","created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"bytes":4173,"created_at":"2022-09-19T17:45:12Z","url":"http://res.cloudinary.com/takeda/image/upload/v1663609512/Takeda%20Oncology/medicine_2_hnvdeo.svg","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663609512/Takeda%20Oncology/medicine_2_hnvdeo.svg","version":1663609512,"public_id":"Takeda Oncology/medicine_2_hnvdeo","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"access_mode":"public","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAJ1BMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCqNwrDBAAAADXRSTlMAYjdnDH5KV3IeJj+Pn5i0WwAAAENJREFUCNdjYODqSGBgYHCV3AQkKxncGRg4BRiUGBiYxVwMGBi0uVrNVBgMuKJNcxgKmFoDZRhM2BQYmBkmihcKigEA+/oI1qJ/5zIAAAAASUVORK5CYII="},"title":"Medicines","titleUrl":"/medicines/","image":{"priority":false,"url":{"format":"jpg","resource_type":"image","bytes":2067345,"created_at":"2022-10-10T19:27:04Z","uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"type":"cloudinary.asset","access_mode":"public","created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"url":"http://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg","width":4800,"height":2700,"version":1665430024,"public_id":"Takeda Oncology/New Images from Simo/Medicine_cnlk3n","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"Oncology medicine ","aspectRatio":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAe1BMVEXGw8b18++9uoHa3bna2JS+q6fRw8Tq6ePd19W0nJ7UzcXX0K7u5JOurbTVtqrfoW3Fo6HJvL3RyZrJrpPfq6fCnInRz7rsysXYyYDIs7Pao53nu7PEzX/mz8HGqpTDsaW/m2zEuLShsra5sqHfx3Xp26Di0Kyov8fn1nmMvikoAAAAQklEQVQI1wXBhQHAIAADsOIOc3f//8IlgJS91Qi5AYQw+7rMMYNSDWN0SymiHWs6cWePF9VQdt5/1xlAiHIFvx+tf27KA7zeuU1FAAAAAElFTkSuQmCC"},"__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"},{"title":"Patients","titleUrl":"/patients/","image":{"altText":"altText of the image","aspectRatio":"","priority":false,"url":{"resource_type":"image","type":"cloudinary.asset","created_by":{"type":"user","id":"04d130f601569775b61d24b8dedb74"},"height":5773,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"jpg","created_at":"2022-10-24T20:38:27Z","uploaded_by":{"type":"user","id":"04d130f601569775b61d24b8dedb74"},"width":8660,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1666643907/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo.jpg","bytes":1713467,"url":"http://res.cloudinary.com/takeda/image/upload/v1666643907/Takeda%20Oncology/New%20Images%20from%20Simo/patient_yi4vvo.jpg","version":1666643907,"access_mode":"public","public_id":"Takeda Oncology/New Images from Simo/patient_yi4vvo","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAHCAMAAAAGcixRAAAAV1BMVEX9+/bQrI1UODLNs5bn2cn69evctI/+/v79/frq1ryEal758OP8+O/47dnz4cjUvqSviHfozqq9trHZ0cr07+ju59vbt6XOpn+df2+TV0e6nH95VUlZPDerJqYSAAAARElEQVQIHQXBBQLAIAwAsUNbbDDX/79zCSoiqusCqIjEMOwGFdT4494DpUI3/sqJlKbJnT1/njm1EqPL1tMC1Tzjte4HXlAClCL2vE0AAAAASUVORK5CYII="},"icon":{"altText":"patient","aspectRatio":"","priority":false,"url":{"created_at":"2022-09-19T17:50:58Z","public_id":"Takeda Oncology/examination_kzjiz6","created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"version":1663609858,"resource_type":"image","width":512,"height":512,"url":"http://res.cloudinary.com/takeda/image/upload/v1663609858/Takeda%20Oncology/examination_kzjiz6.svg","uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"bytes":4554,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"svg","access_mode":"public","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663609858/Takeda%20Oncology/examination_kzjiz6.svg","type":"cloudinary.asset","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAJFBMVEXhJCpHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrEQGB4AAAADHRSTlNLAC8EYFQUDGwie2dSOExpAAAARElEQVQI12MQVGU3NmYQY07wVGUQc/VgFGAQWqwVnsAgyNpWEs5QwOKgNJGBTUyNYSIDu/AKV0OGDsGiRYIMEQwsOwUBN48LkvcnkywAAAAASUVORK5CYII="},"__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"},{"icon":{"altText":"bar chart","aspectRatio":"","priority":false,"url":{"height":512,"version":1663611022,"public_id":"Takeda Oncology/bars_jdlvhq","uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663611022/Takeda%20Oncology/bars_jdlvhq.svg","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"svg","access_mode":"public","bytes":4356,"width":512,"created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"url":"http://res.cloudinary.com/takeda/image/upload/v1663611022/Takeda%20Oncology/bars_jdlvhq.svg","created_at":"2022-09-19T18:10:22Z","type":"cloudinary.asset","resource_type":"image","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAIVBMVEXhJCpHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCoMImqYAAAAC3RSTlMvAE1VJ0JeOBkPaexQlEEAAAA6SURBVAjXYxAUFJR0ZACS0xaByElgUtiCQbBZXc2CQUK1nMmFYVKQWbILg0OqUrALQ+niNKtQBjAAAEHHCx2KQWOBAAAAAElFTkSuQmCC"},"title":"Investors","titleUrl":"https://www.takeda.com/investors/","image":{"url":{"format":"jpg","width":4800,"url":"http://res.cloudinary.com/takeda/image/upload/v1665432536/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9.jpg","created_at":"2022-10-10T20:08:56Z","created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"version":1665432536,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"access_mode":"public","public_id":"Takeda Oncology/New Images from Simo/investor_eqnle9","uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665432536/Takeda%20Oncology/New%20Images%20from%20Simo/investor_eqnle9.jpg","height":2700,"resource_type":"image","bytes":2006901,"type":"cloudinary.asset","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"Man in business suit","aspectRatio":"","priority":false,"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEVfUz/Hsaathnb59uzNysXg4trt2MFgX1fGurbT0cieloPEqpqMbnqypq6sopSSdV26w8E7MSpWW1ahpKKJgXSpqKBTT0qwc1bbxrqOkY9eWFPd4eTz7+Xl1s9/bU/Qv7GIa1OnqbKHd2LAmYbj3tCah3pjY1tEY2a7AAAAQUlEQVQI1wXBhQGAMAADsM7dcHf4/0QSCCI4mZmxgOzlQFeWNqBJsZ3G5bgsCkpXqdvtJz68StXUBY+c+RO10cH/bKUDhkRDHEYAAAAASUVORK5CYII="},"__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"},{"image":{"elementId":"","altText":"altText of the image","aspectRatio":"16:9","priority":false,"url":{"url":"http://res.cloudinary.com/takeda/image/upload/v1665433818/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu.jpg","bytes":1716561,"access_mode":"public","uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"width":4800,"type":"cloudinary.asset","public_id":"Takeda Oncology/New Images from Simo/partnership_txmvgu","height":2700,"created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"format":"jpg","resource_type":"image","created_at":"2022-10-10T20:30:18Z","version":1665433818,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665433818/Takeda%20Oncology/New%20Images%20from%20Simo/partnership_txmvgu.jpg","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEXa3MeSiHtugIdviKB2kZqJlpKqnJSsq6dvf5aSkoydp6lXP0Wwv8WqpqHJwsGgsbjs6NrEurZ0lqGPfXdheHrBs6fBr6hNTUhqXVK6p6Glr62TmJTq6s6Rh5jj48d+lKGhqbXTz8iysqXDw72FioqCdHS+vbtEmgfUAAAAQklEQVQIHQXBhQGAMAADsM5dcIeh/59IgkZOfRVzBkBkp75wX+uOkRilvA0ABmGWJyV/vmipmO1BS3TgNdeMab25H3dcA30EaLpFAAAAAElFTkSuQmCC"},"icon":{"aspectRatio":"","priority":false,"url":{"width":512,"resource_type":"image","bytes":5319,"format":"svg","created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"public_id":"Takeda Oncology/handshake_jpvdgf","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663610049/Takeda%20Oncology/handshake_jpvdgf.svg","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"type":"cloudinary.asset","height":512,"version":1663610049,"access_mode":"public","created_at":"2022-09-19T17:54:09Z","url":"http://res.cloudinary.com/takeda/image/upload/v1663610049/Takeda%20Oncology/handshake_jpvdgf.svg","uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"handshake icon","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAIVBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCo9B3drAAAAC3RSTlMAJ1toChJHO1N8MVSpe/0AAAA3SURBVAjXY2AAA1YgDmAQ0qoSUmRIF0oJLGTQCEpLbWKQMHIQVmRgsTQ0dmBgcJ6ZAFIbwgAFAO2/B9Tajn2XAAAAAElFTkSuQmCC"},"title":"Partnerships","titleUrl":"/partnerships/","__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"},{"icon":{"priority":false,"url":{"url":"http://res.cloudinary.com/takeda/image/upload/v1663611777/Takeda%20Oncology/goal_s13vo4.svg","resource_type":"image","created_at":"2022-09-19T18:22:57Z","type":"cloudinary.asset","bytes":5490,"version":1663611777,"access_mode":"public","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"svg","public_id":"Takeda Oncology/goal_s13vo4","uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"width":512,"height":512,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663611777/Takeda%20Oncology/goal_s13vo4.svg","created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"goal icon","aspectRatio":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKBAMAAAB/HNKOAAAAMFBMVEVHcEzhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCrhJCr59l8uAAAAEHRSTlMACAJvU3wXXGdBJThOiy6j25XIHQAAAD5JREFUCNdjYGBg2GIIJISmA0mmiigFIPtoG5Bgct8GJBltTRYwMLDFN05gYEi+5ziBIbvLaeEEhvA7MSFGAEvzDhWK5bmKAAAAAElFTkSuQmCC"},"title":"Oncology Careers","titleUrl":"/about/careers/","image":{"elementId":"","altText":"altText of the image","aspectRatio":"4:3","priority":false,"url":{"uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"version":1665432141,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665432141/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord.jpg","bytes":1803583,"type":"cloudinary.asset","access_mode":"public","public_id":"Takeda Oncology/New Images from Simo/Careers_j9yord","resource_type":"image","height":2700,"created_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"format":"jpg","created_at":"2022-10-10T20:02:21Z","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"url":"http://res.cloudinary.com/takeda/image/upload/v1665432141/Takeda%20Oncology/New%20Images%20from%20Simo/Careers_j9yord.jpg","width":4800,"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAGCAMAAADNLv/0AAAAdVBMVEX9++u6pJRSVE63rZiHfW+bhneTlYP6+fPf2ML19Nx8SzZVOjfZ1MzJtJ1hUz9xTTXLuqzw7+bYzMSymYzSxsKQeGri5MyScl+Gb2qZd2NoMCGukoWfdFre2tW0jnNZOyrt6tD08uazmH/UwLXBvruFgoV5YlDdifmZAAAARElEQVQIHQXBhQHAIBAEsIMCj1N3obr/iE1QAkSNFLoHAypqO64MPqPvrWZCGcQc/OvZMC2I4eLu2Vc7otCnPFKys/sBYdIDdEgDooIAAAAASUVORK5CYII="},"__metadata":{"modelName":"ImageWithLink","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageWithLink"}],"elementId":"","backgroundColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"titleColor":{"color":"dark-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"columns":3,"excludeFromNavigation":false,"title":"## About Takeda Oncology\n\n","padding":{"left":"0","bottom":"10","right":"0","top":"10"},"hideTitle":false,"__metadata":{"modelName":"TopicsSection","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"TopicsSection"},{"hideTitle":true,"title":"# Divider Section","elementId":"","titleColor":{"color":"dark-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"divider":{"dividerColor":{"color":"light-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"__metadata":{"modelName":"Divider","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Divider"},"displayName":"","backgroundColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"excludeFromNavigation":true,"__metadata":{"modelName":"DividerSection","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"DividerSection"},{"elementId":"","hideTitle":false,"titleColor":{"color":"dark-grey","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"displayName":"","viewAllLink":{"url":"/news/our-viewpoints/","altText":"View all","label":"View all","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},"backgroundColor":{"color":"white","__metadata":{"modelName":"ThemeColorPicker","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ThemeColorPicker"},"excludeFromNavigation":true,"title":"# Our Viewpoints\n\n","__metadata":{"modelName":"NewsroomHotNewsSection","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"NewsroomHotNewsSection","articles":[{"title":"Living is More Than Surviving: Balancing Clinical Outcomes with Patient Impact","taxonomies":[{"displayName":"Patients","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"5AQ1D5ZjReEmtg97GZdhmX","createdAt":"2022-10-26T16:28:23Z","updatedAt":"2023-06-08T11:31:34Z"},"type":"Taxonomy"},{"displayName":"our-viewpoints","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E13B866B-3078-4828-ACC7-6843A32C1074","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Taxonomy"}],"publishDate":"2024-05-29T15:26:00.000Z","content":"**Author: Awny Farajallah, M.D., Chief Medical Officer, Global Oncology Business Unit**\n\nOver the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. This has led to a stronger focus on survival outcomes, and, in some cancers, many patients are living longer on treatment than ever before thanks to therapeutic developments such as novel targeted therapies and immunotherapy. The improvement in survival rates has created an opportunity  and obligation  to consider factors beyond just survival rates when it comes to the management of the disease.\n\nAs we continue to advance treatment options, there has been a growing movement towards prioritizing patient-centered care  considering the individual health status, preferences, values, and goals of patients when making treatment decisions. Balancing clinical outcomes with the real-world experiences of patients can be complex but is necessary to provide the best possible care. \n\n## Redefining Survival: The Dramatic Impact of Targeted Therapy\n\nLets dive a little deeper into one of the reasons weve observed such notable improvements in the survival rates for certain cancer types  targeted therapies. Targeted therapies have revolutionized the way some cancers are treated by enabling us to target a genetic mutation that may be driving the cancer. This scientific achievement has dramatically changed the prognosis for certain types of cancers, such as breast and lung.\n\nFor example, breast cancer is the second-most common and lethal cancer type in women, and treatment options were previously limited to chemotherapies, radiation, and surgical procedures. For HER2-positive breast cancers specifically, which account for about 20% of all breast cancers, the disease is more aggressive and has a worse prognosis. The development of HER2-targeted drugs has forever changed the treatment approach and patient outcomes. In fact, some treatment combinations for this cancer extend survival to more than 4.5 years, compared to a life expectancy of 1.5 years achieved 14 years ago.\u003csup\u003e1\u003c/sup\u003e\n\nA similar transformation has occurred in the treatment of non-small cell lung cancer (NSCLC), another widespread cancer that has been historically difficult to treat and was previously treated with chemotherapy, radiotherapy or a combination of both. Over time, weve learned that about 70% of patients with NSCLC have a targetable mutation, such as EGFR, BRAF, ALK or KRAS. With improved diagnostic testing, these patients are being matched with treatments that target their cancer at its source. As a result, in recent years, population-level mortality from NSCLC has fallen sharply.\u003csup\u003e2\u003c/sup\u003e\n\nIn addition to longer survival durations, some targeted therapies have also improved upon the toxicity profiles and administration of standard chemotherapies. For example, in a study comparing neoadjuvant targeted therapy versus neoadjuvant chemotherapy in advanced-stage EGFR-mutant NSCLC, the incidence of grade 3/4 adverse events was found to be significantly less in the targeted therapy group compared to the chemotherapy group.\u003csup\u003e3\u003c/sup\u003e Many of these targeted therapies are administered orally, providing a more convenient dosing regimen for patients.\u003csup\u003e4-10\u003c/sup\u003e \n\nIn the 20+ years since the first targeted therapies for cancer were introduced, they have revolutionized the diagnosis and treatment of patients with breast cancer, lung cancer and many other types of cancer, and made the possibility of extending patients lives while improving convenience, adherence and safety, a reality.\u003csup\u003e11\u003c/sup\u003e  \n\n## From Survival to Survivorship \n\nWhile the rise in survival rates is an incredible accomplishment that will continue to be built upon as science advances, it has also brought about a paradigm shift in cancer care. With more cancer survivors living longer and more therapeutic options than ever before, there is greater impetus to evolve how we evaluate factors to identify the best treatment for each patient. \n\nFor example, quality of life (QoL) and method of treatment administration are important real-world factors that should be considered in addition to clinical outcomes, as they play a crucial role in the everyday lives and experiences of patients. \n\nThat said, how they are viewed and prioritized can differ by patient. For example, some patients may prioritize convenience and flexibility in treatment administration, while others may be more concerned about potential side effects or the impact of treatment on their ability to work or socialize. Some patients may prefer oral therapies that can be taken at home, while others may be comfortable with intravenous therapies administered in a clinical setting.\n\nEvaluating these factors alongside traditional clinical standards when determining the best possible treatment ensures we are taking not only a patients survival into account  but also their quality of survivorship. Survivorship, in the context of cancer, refers to the journey and life experiences patients must navigate following their cancer diagnosis. Despite advancements in care over the past decade, there are still substantial gaps and challenges that need to be addressed to alleviate the short- and long-term effects of treatments  such as fatigue, cognitive problems, and pain  and their impact on an individuals survivorship and long-term disease management. \n\nBecause real-world factors and their role in survivorship are often not measured in randomized clinical trials, its crucial we invest in real-world evidence research and partner with patients and advocacy groups to understand how patients experience and prioritize factors such as location, family type, socioeconomic status, mental health, support systems, and cultural background and how these considerations influence their decisions.\n\nUltimately, the goal is to provide patients with the best possible opportunity of achieving long-term survival while also maintaining a good quality of life. This requires a collaborative effort between patients, their healthcare providers, and the healthcare industry to ensure that the unique needs and preferences of each patient are considered to improve care. \n\n## Looking Ahead\n\nWhile clinical outcomes will continue to be paramount, as treatment options improve, it is imperative that additional factors are considered, and patients are actively involved in the decision-making process.  Considering patient preferences on factors like quality of life, treatment feasibility and emotional well-being alongside considerations on clinical efficacy can help optimize outcomes and patient experience. \n\nBy prioritizing an environment of trust, shared decision-making, and open communication, we can empower individuals to actively participate in their treatment journeys and become informed partners in their own care, which has been shown to improve their perception of quality of care and conversations with physicians.\u003csup\u003e12\u003c/sup\u003e\n\nThe future of cancer treatment lies in embracing an approach that considers a complete picture of patient health, recognizing not only survival as a key outcome but also incorporating the patient's overall well-being, or survivorship. By integrating real-world factors into treatment decision-making, prioritizing patient-centered care, and fostering ongoing research, we can collectively transform the cancer survivorship landscape and, hopefully, empower individuals worldwide to lead fulfilling lives beyond their diagnosis.\n\n## References\n\n1. Mendes D, Alves C, Afonso N, et al. The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer  a systematic review. Breast Cancer Res 17, 140 (2015). https://doi.org/10.1186/s13058-015-0648-2\n2. Howlader H, Forjaz G, Mooradian M, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020;383:640-649. Published 2020 Aug 12. DOI: 10.1056/NEJMoa1916623\n3. Chen D, Jin Z, Zhang J, et al. Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021;8:715318. Published 2021 Aug 19. doi:10.3389/fsurg.2021.715318\n4. Assoun S, Lemiale V, Azoulay E. Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Med. 2019;45(7):988-997. doi:10.1007/s00134-019-05650-w\n5. Atrium Health. Treating Stage IV Lung Cancer With a Pill. Available at: https://atriumhealth.org/dailydose/2018/01/10/treating-stage-iv-lung-cancer-with-a-pill\n6. XALKORI Prescribing Information. Pfizer. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=676\n7. ZYKADIA Prescribing Information. Novartis. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/zykadia.pdf\n8. ALECENSA Prescribing Information. Genentech. Available at: https://www.gene.com/download/pdf/alecensa_prescribing.pdf\n9. LORBRENA Prescribing Information. Pfizer. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=11140\n10. ALUNBRIG Prescribinig Information. Takeda. Available at: https://www.alunbrig.com/sites/default/files/2022-10/prescribing-information.pdf\n11. American Cancer Society. History of Cancer Treatments: Targeted Therapy. Available at: https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-targeted-therapy.html\n12. Kehl KL, Landrum MB, Arora NK, et al. Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. JAMA Oncol. 2015;1(1):5058. doi:10.1001/jamaoncol.2014.112\n","description":"Over the past several decades, the rapid pace of scientific advancement has catalyzed a revolution in the way we treat cancers. Takeda Oncology  Leadership  Article","featuredImg":{"url":"http://assets-dam.takeda.com/image/upload/v1716991916/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More.png","uploaded_by":{"id":"553579438111562","type":"accesskey"},"folder":"Takeda Oncology/News/our-viewpoints","id":"b9e27c6a7a072900e001199adc6a191d","version":1716991916,"folder_id":"c1e80517a809460d7004a5152963235b6c","height":720,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"bytes":76242,"format":"png","public_id":"Takeda Oncology/News/our-viewpoints/16x9_Living-Is-More","secure_url":"https://assets-dam.takeda.com/image/upload/v1716991916/Takeda%20Oncology/News/our-viewpoints/16x9_Living-Is-More.png","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"access_mode":"public","width":1280,"_version":1,"created_at":"2024-05-29T14:11:56Z","type":"cloudinary.asset","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"visibleInListings":true,"slug":"/news/our-viewpoints/living-is-more-than-surviving","__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"3066293e-640b-498f-8a53-9e8c9d50ea81","createdAt":"2024-05-27T16:45:47Z","updatedAt":"2024-05-29T23:07:29Z"},"type":"Article"},{"slug":"/news/our-viewpoints/beyond-early-detection-bridging-the-gaps-in-metastatic-colorectal-cancer-support","publishDate":"2024-02-29T15:26:00.000Z","taxonomies":[{"displayName":"Patients","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"5AQ1D5ZjReEmtg97GZdhmX","createdAt":"2022-10-26T16:28:23Z","updatedAt":"2023-06-08T11:31:34Z"},"type":"Taxonomy"},{"displayName":"our-viewpoints","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E13B866B-3078-4828-ACC7-6843A32C1074","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Taxonomy"}],"visibleInListings":true,"title":"Beyond Early Detection: Bridging the Gaps in Metastatic Colorectal Cancer Support","content":"In the United States, colorectal cancer (CRC) is the third leading cause of cancer-related deaths, with a projected toll of over 50,000 deaths in 2024. Overall, the lifetime risk of developing CRC is about 1 in 23 for men and 1 in 25 for women.\u003csup\u003e1\u003c/sup\u003e\n\nWhen people are diagnosed with later stage or more advanced CRC, it is known as metastatic CRC (mCRC).\u003csup\u003e2\u003c/sup\u003e When a cancer metastasizes, it means that cancer cells have spread to other parts of the body.\u003csup\u003e3\u003c/sup\u003e When caught early, CRC is often treatable and, in many cases, curable, speaking to the importance of screening and early detection. However, at least 20% of people are diagnosed with CRC in the metastatic stage, and about 50% of people diagnosed with localized CRC will develop metastases over the course of their disease.\u003csup\u003e4,5\u003c/sup\u003e After cancer metastasizes, treatment can become much more challenging and as a result, many people experience diminished survival outcomes and quality of life.\u003csup\u003e6\u003c/sup\u003e\n\n## A Prevalent Cancer, A Lack of Support\n\nWhile CRC ranks among the most prevalent types of cancers, there are still considerable gaps in care and resources for patients, particularly for those experiencing structural challenges and barriers that impact both treatment access and survival outcomes.\n\nThe distribution of CRC and mCRC is not even across U.S. subpopulations; there is a marked difference in incidence among different racial and ethnic groups. For example, Black Americans are about 20% more likely to get CRC and about 40% more likely to die from it than any other racial group in the U.S.\u003csup\u003e7\u003c/sup\u003e Additional factors that could impact disease experience with CRC are socioeconomic status, insurance access, geography and environmental exposure, among others.\n\n\u003e There is a wealth of information available around screening and prevention of CRC, but educational resources are sparse by comparison for patients with advanced CRC. While early detection of CRC is the hope, the unfortunate truth is that many people are either diagnosed with advanced CRC or will progress to it over time. Recognizing the challenges and diverse experience of those with mCRC is not widely documented. There is a critical need to develop comprehensive resources to assist the broader community in providing better support, particularly as new treatment options and combinations emerge, offering people more decisions to navigate.\n\u003e\n\u003e **ASHLEY CALABRESE**\n\u003e Associate Director, Policy and Advocacy, US Public Affairs\n\n## A United Purpose to Support Advanced CRC Patients\n\nJoined by a passion to make a difference for advanced CRC patients, Takeda and four leading advocacy organizations are launching a U.S. survey to identify the most pressing needs concerning disease and treatment navigation. Through this collaborative effort, we intend to uncover actionable insights that will help guide the collective development of resources and education to support patients. Our partners include:\n\n**Colorectal Cancer Alliance:** Founded 25 years ago by more than 40 CRC survivors, caregivers and friends, the Alliance advocates for screening, magnifies patient support and accelerates research. It exists to end CRC in our lifetime.\n\n**COLONTOWN:** Founded by a CRC survivor looking to create a disease-specific community, COLONTOWN empowers proactive colorectal cancer patients and caregivers with educational tools and relevant peer-to-peer support.\n\n**BLKHLTH:** BLKHLTH is an Atlanta-based non-profit with a mission to advance the health of Black communities through equity-centered education, advocacy, research and programs.\n\n**Family Reach:** Family Reach is a non-profit that provides non-medical financial support to people facing cancer. They work with patients, providers and community organizations to challenge the systems that force families to choose between their health and their home.\n\nWe will be unveiling findings for the survey throughout 2024. To learn more about our partners we are collaborating with, please visit their channels: [Colorectal Cancer Alliance](https://colorectalcancer.org/), [COLONTOWN](https://colontown.org/), [BLKHLTH](https://www.blkhlth.com/) and [Family Reach](https://familyreach.org/).\n\n## References\n\n1.  American Cancer Society. Key Statistics for Colorectal Cancer. Available at: \u003chttps://www.cancer.org/cancer/types/colon-rectal-cancer/about/key-statistics.html\u003e\n\n2.  Memorial Sloan Kettering Cancer Center. Treatment for Metastatic Colon Cancer. Available at: \u003chttps://www.mskcc.org/cancer-care/types/colon/treatment/metastases\u003e\n\n3.  City of Hope Cancer Treatment Centers. Metastatic Colorectal Cancer (stage 4). Available at: \u003chttps://www.cancercenter.com/cancer-types/colorectal-cancer/types/metastatic-colorectal-cancer\u003e\n\n4.  Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669-685. doi:10.1001/jama.2021.0106\n\n5.  Atreya CE, Yaeger R, Chu E. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches. Am Soc Clin Oncol Educ Book. 2017;37:246-256. doi:10.1200/EDBK_175679\n\n6.  American Cancer Society. Treatment of colon cancer, by stage. Available at: \u003chttps://www.cancer.org/cancer/types/colon-rectal-cancer/treating/by-stage-colon.html\u003e\n\n7.  American Cancer Society. Colorectal Cancer Rates Higher in African Americans, Rising in Younger People. Available at: \u003chttps://www.cancer.org/cancer/latest-news/colorectal-cancer-rates-higher-in-african-americans-rising-in-younger-people.html\u003e\n\n\n","featuredImg":{"resource_type":"image","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"uploaded_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"folder_id":"c1e80517a809460d7004a5152963235b6c","version":1709145929,"format":"png","created_at":"2024-02-28T18:45:29Z","_version":1,"width":1920,"id":"632cf2e2b734b8b7a06bbe65939ad58a","access_mode":"public","bytes":191085,"public_id":"Takeda Oncology/News/our-viewpoints/Beyond Early Detection","secure_url":"https://assets-dam.takeda.com/image/upload/v1709145929/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection.png","type":"cloudinary.asset","url":"http://assets-dam.takeda.com/image/upload/v1709145929/Takeda%20Oncology/News/our-viewpoints/Beyond%20Early%20Detection.png","height":1080,"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"description":"Beyond early detection, how do we bridge the gap in metastatic colorectal cancer care. Learn about Takedas partnerships for patient support.","__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"acdf9dee-3ade-4000-b599-0028348e1d7f","createdAt":"2024-02-29T19:04:10Z","updatedAt":"2024-09-09T18:17:22Z"},"type":"Article"},{"visibleInListings":true,"authors":[{"fullName":"Teresa Bitetti","additionalInformation":"President, Global Oncology Business Unit","role":"President","__metadata":{"modelName":"Person","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E0EC499F0BCF","createdAt":"2022-12-12T06:39:01Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Person"}],"publishDate":"2024-01-30T20:00:00.000Z","taxonomies":[{"displayName":"Data and Digital","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"j1tWZCfjdAwUaXU7wUc134","createdAt":"2022-12-16T17:49:34Z","updatedAt":"2023-06-08T11:32:09Z"},"type":"Taxonomy"},{"displayName":"our-viewpoints","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E13B866B-3078-4828-ACC7-6843A32C1074","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Taxonomy"}],"content":"Technological advances continue to push the boundaries of what's possible. Takeda's Teresa Bitetti discusses how we are leveraging these tools for cancer patients.\n","slug":"/news/our-viewpoints/embracing-AI-emerging-technologies-to-advance-cancer-care","featuredImg":{"access_mode":"public","version":1705682493,"bytes":883719,"created_at":"2024-01-19T16:41:33Z","url":"http://assets-dam.takeda.com/image/upload/v1705682493/Takeda%20Oncology/News/our-viewpoints/Teresa_DDT_Static_Article_Image.png","secure_url":"https://assets-dam.takeda.com/image/upload/v1705682493/Takeda%20Oncology/News/our-viewpoints/Teresa_DDT_Static_Article_Image.png","id":"ec1b8a618de47e04047a01fa10a0f314","folder_id":"c1e80517a809460d7004a5152963235b6c","resource_type":"image","width":1920,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"format":"png","created_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"height":1080,"public_id":"Takeda Oncology/News/our-viewpoints/Teresa_DDT_Static_Article_Image","uploaded_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"type":"cloudinary.asset","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"description":"Technological advances continue to push the boundaries of what's possible. Takeda's Teresa Bitetti discusses how we are leveraging these tools for cancer patients.","readTime":0,"title":" Embracing AI \u0026 Emerging Technologies to Advance Cancer Care","__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"de9e3207-16b7-412f-8f24-5cc9b89f90b6","createdAt":"2024-01-29T15:53:29Z","updatedAt":"2024-05-30T19:14:55Z"},"type":"Article"},{"description":"Hear from Teresa Bitetti, President of the Global Oncology Business Unit, as she discusses how Takeda and its partners are providing cancer care beyond medicine by supporting other areas of patients' lives, such as finances and mental health.","title":"Cancer Treatment is More Than Medicine","featuredImg":{"type":"cloudinary.asset","height":1080,"format":"png","created_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"resource_type":"image","url":"http://assets-dam.takeda.com/image/upload/v1692027298/Takeda%20Oncology/News/our-viewpoints/Cancer-Treatment-is-More-Than-Medicine.png","secure_url":"https://assets-dam.takeda.com/image/upload/v1692027298/Takeda%20Oncology/News/our-viewpoints/Cancer-Treatment-is-More-Than-Medicine.png","access_mode":"public","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"width":1920,"public_id":"Takeda Oncology/News/our-viewpoints/Cancer-Treatment-is-More-Than-Medicine","uploaded_by":{"id":"ec6a5b13a6920997f0770195fabdbb","type":"user"},"version":1692027298,"bytes":489014,"created_at":"2023-08-14T15:34:58Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"slug":"/news/our-viewpoints/cancer-treatment-is-more-than-medicine","taxonomies":[{"displayName":"Patients","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"5AQ1D5ZjReEmtg97GZdhmX","createdAt":"2022-10-26T16:28:23Z","updatedAt":"2023-06-08T11:31:34Z"},"type":"Taxonomy"},{"displayName":"our-viewpoints","__metadata":{"modelName":"Taxonomy","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E13B866B-3078-4828-ACC7-6843A32C1074","createdAt":"2022-12-12T06:39:00Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Taxonomy"}],"visibleInListings":true,"content":"**Author: Teresa Bitetti, President, Global Oncology Business Unit**\n\nMany of us have loved ones who have been affected by cancer and understand the immense difficulty of processing a diagnosis and beginning treatment, both for the patient and their support network. Through personal and professional conversations with patients, we also recognize that their challenges often extend far beyond the initial diagnosis.\n\nFrom financial and job insecurity, to depression and anxiety, to caregiving responsibilities  cancer treatment can be all-consuming. And while developing innovative medicines to treat cancer is at the heart of what we do as a pharmaceutical company, there is a lesser-known part as critical as the medicine  treating the whole patient. Its this care beyond medicine where we have devoted more support in recent years.\n\n## Mental Health and Well-Being\n\nA cancer diagnosis can take an incredible toll on mental and emotional health, and recognizing changes in mood and behavior are critical during the journey according to the [American Cancer Society](https://www.cancer.org/cancer/managing-cancer/side-effects/emotional-mood-changes.html). Approximately 35% of patients diagnosed with cancer are impacted by a psychiatric disorder, and another 20% experience clinically relevant distressing psychosocial conditions such as demoralization and health anxiety.\u003csup\u003e1 \u003c/sup\u003eResearch has shown that cancer patients receiving mental health support have better outcomes.\u003csup\u003e2 \u003c/sup\u003eUnfortunately, while mental health support may be a key part of a patients treatment journey, it is not always incorporated.\u003csup\u003e3\u003c/sup\u003e\n\nFortunately, there are several ways patients can be supported as they navigate the physical and emotional aspects of cancer. I am impressed by the resources that many of our partner patient advocacy organizations such as [CancerCare](https://www.cancercare.org/) provide  including emotional, practical and financial support  to navigate resources and the underlying emotions associated with diagnosis and treatment.\n\n## Life Necessities and Obligations\n\nA cancer diagnosis does not put life on pause. Patients may still need to feed themselves (and also family members), keep a roof over their heads, continue working, among many other aspects of life. Cancer is stressful enough without the added component of determining how to afford life.\n\nFinancial hardship impacts one in three patients diagnosed with cancer. And the risks disproportionality affect those who are socioeconomically disadvantaged and working-aged patients.\u003csup\u003e4\u003c/sup\u003e The anxiety and stress of affording basic necessities can lead to poorer mental health, which can lead to poorer outcomes, perpetuating a vicious cycle. Fortunately, organizations such as [Family Reach](https://familyreach.org/) provide resources to help patients navigate non-medical expenses. No one should have to make the decision to put treatment on hold to keep food on their table or the lights on at home.\n\nIn addition, patients may also be caregivers  to children, to aging parents, to pets  a role that does not disappear at cancer diagnosis. Caregiving can be emotionally and physically taxing even without managing a cancer diagnosis and treatment. Organizations such as [Cancer Support Community](https://www.cancersupportcommunity.org/) offer resources to support dialogue between patient and those in their care as they navigate this journey together.\n\nCancer treatment is more than medicine. Its the collaboration and commitment of many stakeholders to ensure that patients receive the care necessary to navigate their journey. At Takeda, Im proud we partner with patient organizations around the globe  to raise awareness and provide support to help ensure the whole patient is being treated. This is the way we will truly reach our aspiration to cure cancer.\n\n## References:\n\n1.  Caruso R, Breitbart W. Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions. *Epidemiol Psychiatr Sci.* 2020;29:e86. doi:10.1017/S2045796019000866\n\n2.  Berchuck JE, Meyer CS, Zhang N, et al. Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer. *JAMA Oncol.* 2020;6(7):1055-1062. doi:10.1001/jamaoncol.2020.1466\n\n3.  Oncology TL. Provision of mental health care for patients with cancer. *The Lancet Oncology*. 2021;22(9):1199. doi:10.1016/S1470-2045(21)00480-0\n\n4.  Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. *J Natl Compr Canc Netw.* 2019;17(10):1184-1192. doi:10.6004/jnccn.2019.7305\n\n","publishDate":"2023-08-15T15:26:00.000Z","authors":[{"additionalInformation":"President, Global Oncology Business Unit","role":"President","fullName":"Teresa Bitetti","__metadata":{"modelName":"Person","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"E0EC499F0BCF","createdAt":"2022-12-12T06:39:01Z","updatedAt":"2023-06-08T11:31:45Z"},"type":"Person"}],"__metadata":{"modelName":"Article","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"8b92b846-be2b-4f24-b836-bdf8255bb3df","createdAt":"2023-08-14T15:29:10Z","updatedAt":"2024-10-10T21:22:07Z"},"type":"Article"}]}],"slug":"/","title":"Home","description":"Home","noIndexNoFollow":false,"keywords":"","socialImage":{"uploaded_by":{"id":"04d130f601569775b61d24b8dedb74","type":"user"},"access_mode":"public","version":1665430024,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"width":4800,"format":"jpg","bytes":2067345,"created_at":"2022-10-10T19:27:04Z","url":"http://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg","type":"cloudinary.asset","height":2700,"resource_type":"image","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1665430024/Takeda%20Oncology/New%20Images%20from%20Simo/Medicine_cnlk3n.jpg","public_id":"Takeda Oncology/New Images from Simo/Medicine_cnlk3n","created_by":{"type":"user","id":"04d130f601569775b61d24b8dedb74"},"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"addTitleSuffix":false,"visibleInListings":true,"metaDescription":"Discover Takeda Oncology's decades of leadership in oncology. Explore their approach, latest news, pipeline, and innovative therapies.","site":{"header":{"searchPageUrl":"/search","title":"Takeda Oncology","globalNavDefaultState":"expanded","searchLocationPlaceholder":"Search for a country","defaultColors":"takeda-colors","logo":{"url":{"access_mode":"public","resource_type":"image","format":"svg","width":207,"height":74,"uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"url":"http://res.cloudinary.com/takeda/image/upload/v1663597913/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0.svg","type":"cloudinary.asset","version":1663597913,"public_id":"TAKEDA GLOBAL/takeda_logo_1_pf4uo0","created_at":"2022-09-19T14:31:53Z","created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"bytes":3077,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663597913/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0.svg","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"Takeda logo","aspectRatio":"","priority":false,"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAECAMAAACA5l7/AAAARVBMVEX94OL4rK/2i4/4naD4oqX1h4v4p6r809X6ur395eb5tLf6wsT7ysz5tbj2jpL809X4rK/2kJT70tT5rK/6xcf5tbj6xsilREIhAAAAFnRSTlP9BjroKoNC+aHXb+7v5qWq56ar///+Wg1+4gAAADBJREFUCB0FwQkCABAIBMBFJDfF/59qBo7KEZmFHPxeDHAfHjFc1asaIlJuZs9qTh8gVgGrrAdbegAAAABJRU5ErkJggg=="},"localNavDefaultState":"","searchPlaceholder":"Search...","version":"v2","scrolledDownColors":"takeda-colors","__metadata":{"modelName":"DefaultHeader","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"9252634f-22e7-4042-ada9-0491a16c01b3","createdAt":"2022-07-21T14:11:36Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"DefaultHeader"},"noIndexNoFollow":false,"exitDisclaimer":{"isEnabled":true,"description":"You are now leaving Takedaoncology.com and entering a website that is not owned or controlled by Takeda. \n\nTakeda Oncology makes no representation as to the accuracy of the information contained on websites we do not own or control. Takeda Oncology does not recommend or endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.\n","title":"You are now leaving Takedaoncology.com","cancelButtonTitle":"Cancel","okButtonTitle":"Continue","whitelistedUrls":["assets-dam.takeda.com","takedaoncology.com","www.takedaoncology.com","takeda.com","content.takeda.com","www.takeda.com","takeda.info","www.takeda.info","takedacanada.com","www.takedacanada.com","takedajobs.com/oncology","www.takedajobs.com/oncology","clinicaltrials.takeda.com","www.clinicaltrials.takeda.com","velcade.com","www.velcade.com","velcade-hcp.com","www.velcade-hcp.com","ninlaro.com","www.ninlaro.com","ninlarohcp.com","www.ninlarohcp.com","exkivityhcp.com","www.exkivityhcp.com","exkivity.com","www.exkivity.com","iclusig.com","www.iclusig.com","alunbrig.com","www.alunbrig.com","tsupportportal.com","www.tsupportportal.com","here2assist.com","www.here2assist.com","secure.ethicspoint.com/domain/media/en/gui/28267/index.html","takeda.envisionpharma.com/vt_takeda","cookiepedia.co.uk/giving-consent-to-cookies","www.cookiepedia.co.uk/giving-consent-to-cookies","instagram.com/TakedaOncology","www.instagram.com/TakedaOncology","twitter.com/takedaoncology","www.twitter.com/takedaoncology","facebook.com/takedaoncology","www.facebook.com/takedaoncology","linkedin.com/company/takedaoncology","www.linkedin.com/company/takedaoncology"],"__metadata":{"modelName":"ExitDisclaimer","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ExitDisclaimer"},"footer":{"logo":{"aspectRatio":"","priority":false,"url":{"resource_type":"image","context":{"custom":{"Language":"English","alt":"Takeda logo","caption":"Takeda logo"}},"created_at":"2022-05-11T09:09:23Z","uploaded_by":{"id":"553579438111562","type":"accesskey"},"bytes":3692,"width":720,"access_mode":"public","url":"http://res.cloudinary.com/takeda/image/upload/v1652260163/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257.svg","version":1652260163,"created_by":{"id":"553579438111562","type":"accesskey"},"public_id":"migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257","secure_url":"https://res.cloudinary.com/takeda/image/upload/v1652260163/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257.svg","type":"cloudinary.asset","format":"svg","tags":["Takeda Logo","Takeda","logo"],"height":256,"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","altText":"altText of the image","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAECAMAAACA5l7/AAAAOVBMVEX4yMn86er4ycv0rrHuf4P3w8X50tNHcEz4zs/ugob73t/0rK763t/wlJfynaD86uv++PjzqKv1t7mDF9BrAAAADXRSTlP+Csdqs60qABrD7/7v1KBqGwAAAC1JREFUCNcdwgESABAIBMBLqJDw/8cydhZCnNpITAK1HrEWTJH3cZ9vRi34Sr0beAEtjhAsjAAAAABJRU5ErkJggg=="},"copyrightText":"All trademarks are the property of their respective owners.\n\n2025 Takeda Pharmaceuticals U.S.A., Inc.\n\nAll rights reserved. 01/23\n","socialLinks":[{"url":"http://www.instagram.com/TakedaOncology","elementId":"","altText":"","icon":{"variant":"Instagram","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Instagram","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"icon":{"variant":"Facebook","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Facebook","url":"facebook.com/takedaoncology","elementId":"","altText":"facebook","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"icon":{"variant":"Twitter","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Twitter","url":"https://twitter.com/takedaoncology","elementId":"","altText":"","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"url":"https://www.linkedin.com/company/takedaoncology","elementId":"","altText":"","icon":{"variant":"LinkedIn","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"LinkedIn","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"}],"__metadata":{"modelName":"DefaultFooter","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"2fteZ9Y1L8iF6RDIFNFz2C","createdAt":"2022-09-20T09:31:47Z","updatedAt":"2025-02-18T18:35:08Z"},"type":"DefaultFooter"},"globalLanguages":[{"isDefault":false,"additionalLinks":[{"altText":"Privacy Notice","url":"https://www.takeda.com/privacy-notice/","icon":"LinkExternal","showIcon":true,"elementId":"","label":"Privacy Notice","iconPosition":"right","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"iconPosition":"right","label":"Terms of Use","showIcon":true,"url":"https://www.takeda.com/terms-of-use/","altText":"","icon":"LinkExternal","elementId":"","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"iconPosition":"right","label":"Social Media Policy","elementId":"","altText":"Social Media Policy","url":"/social-media-policy/","icon":"arrowRight","showIcon":false,"__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"altText":"","icon":"arrowRight","label":"Contact Us","url":"/about/contact-us/","elementId":"","iconPosition":"right","showIcon":false,"__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"}],"displayName":"English","links":[{"iconPosition":"right","label":"About","elementId":"","showIcon":false,"url":"/about/","altText":"About Takeda Oncology","icon":"arrowRight","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"icon":"arrowRight","url":"/science/","elementId":"","iconPosition":"right","showIcon":false,"label":"Science","altText":"Science","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"url":"/medicines/","showIcon":false,"elementId":"","altText":"Medicines","icon":"arrowRight","iconPosition":"right","label":"Medicines","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"elementId":"","altText":"Patients","iconPosition":"right","url":"/patients/","icon":"arrowRight","showIcon":false,"label":"Patients","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"url":"/partnerships/","altText":"Partnerships","icon":"arrowRight","showIcon":false,"iconPosition":"right","label":"Partnerships","elementId":"","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"url":"/newsroom/","label":"Newsroom ","altText":"Newsroom","iconPosition":"right","elementId":"","icon":"arrowRight","showIcon":false,"__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"url":"https://www.takeda.com/investors/","icon":"arrowRight","elementId":"","label":"Investors ","showIcon":false,"altText":"Investors","iconPosition":"right","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"}],"languageCode":"en","__metadata":{"modelName":"GlobalLanguage","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"GlobalLanguage"}],"fallbackSocialImage":{"format":"svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","uploaded_by":{"id":"553579438111562","type":"accesskey"},"width":1080,"url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"bytes":3685,"created_at":"2023-01-31T18:17:13Z","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","created_by":{"id":"553579438111562","type":"accesskey"},"resource_type":"image","secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","access_mode":"public","type":"cloudinary.asset","height":599,"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"scripts":[{"title":"AIM-TAG","script":{"language":"js","code":"\u003cscript defer nomodule src=\"https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer\u0026target=ie11\"\u003e\u003c/script\u003e\r\n\u003cscript defer type=\"module\" src=\"https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer\"\u003e\u003c/script\u003e\r\n\u003cscript defer\u003e\r\nwindow.aimDataLayer = window.aimDataLayer || [];\r\nfunction aimTag() { aimDataLayer.push(arguments); }\r\n// Transition event is temporary during a limited period of time to allow us to pull application cache from Legacy AIM Reader (v2) over to AIM Tag (v4)\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'transition');\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'pageview');\r\n// If your contract includes signal, then callback will include personal information on the visitor\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'signal', function(err, success) {\r\n    if (err) {\r\n        // This will occur if we disable your API Key\r\n        console.log(err);\r\n    } else {\r\n        console.log(success);\r\n        if (success.identity_type === \"AUT\") {\r\n            // Handle signal callback here\r\n        }\r\n    }\r\n});\r\n\u003c/script\u003e","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"loadingStrategy":"beforeInteractive","__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"loadingStrategy":"beforeInteractive","title":"OneTrust Script","script":{"code":"\u003c!-- OneTrust Cookies Consent Notice start for takedaoncology.com --\u003e\n\u003cscript defer type=\"text/javascript\" src=\"https://cdn.cookielaw.org/consent/1c21da89-fd19-457f-a6d0-69a1c4fead2d/OtAutoBlock.js\" \u003e\u003c/script\u003e\n\u003cscript defer src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" data-document-language=\"true\" type=\"text/javascript\" charset=\"UTF-8\" data-domain-script=\"1c21da89-fd19-457f-a6d0-69a1c4fead2d\" \u003e\u003c/script\u003e\n\u003cscript defer type=\"text/javascript\"\u003e\nfunction OptanonWrapper() { }\n\u003c/script\u003e\n\u003c!-- OneTrust Cookies Consent Notice end for takedaoncology.com --\u003e","filename":"","language":"","highlightedLines":[2],"__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"loadingStrategy":"beforeInteractive","title":"GTA Script","script":{"code":"\u003c!-- Google Tag Manager --\u003e\n\u003cscript\u003e(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':\nnew Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],\nj=d.createElement(s),dl=l!='dataLayer'?'\u0026l='+l:'';j.async=true;j.src=\n'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);\n})(window,document,'script','dataLayer','GTM-WLM2GHB');\u003c/script\u003e\n\u003c!-- End Google Tag Manager --\u003e","filename":"","language":"","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"loadingStrategy":"beforeInteractive","title":"Matomo Tag Manager ","script":{"code":"\u003c!-- Matomo Tag Manager --\u003e\u003cscript\u003e\nvar _mtm = window._mtm = window._mtm || [];\n_mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'});\nvar d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];\ng.async=true; g.src='https://cdn.matomo.cloud/takeda.matomo.cloud/container_8RFPFIX1.js'; s.parentNode.insertBefore(g,s);\n\u003c/script\u003e\u003c!-- End Matomo Tag Manager --\u003e","language":"","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"title":"CSS Hack for one trust","script":{"language":"","code":"\u003cstyle type=\"text/css\"\u003e #onetrust-consent-sdk svg {display: inline;} \u003c/style\u003e","filename":"","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"loadingStrategy":"beforeInteractive","__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"}],"__metadata":{"modelName":"Config","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"IV5sQe0KJfPcurPYxLZQeL","createdAt":"2022-07-21T14:11:21Z","updatedAt":"2025-03-19T12:34:30Z"},"type":"Config"},"theme":{"colorDarkGrey":"#34373f","colorSecondary":"#ffffff","textColor":"#333333","colorPrimaryActiveContrast":"#ffffff","colorPrimaryContrast":"#ffffff","colorDarkGreyContrast":"#ffffff","colorLightGrey":"#edf2f4","colorMediumGreyContrast":"#ffffff","colorMediumGrey":"#8289A5","colorPrimary":"#bd120a","colorLightGreyContrast":"#34373f","colorSecondaryContrast":"#34373f","colorPrimaryActive":"#891515","__metadata":{"modelName":"ThemeStyle","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"2c32cbf6-3c2c-45c9-ba61-912e076f9e03","createdAt":"2022-09-02T06:01:20Z","updatedAt":"2023-06-08T11:31:22Z"},"type":"ThemeStyle"},"__metadata":{"modelName":"ContentLayout","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"a8d23517-8dcf-4abb-bb2c-888f0fac92bc","createdAt":"2022-07-21T13:56:44Z","updatedAt":"2023-12-14T17:16:56Z"},"type":"ContentLayout"},"site":{"fallbackSocialImage":{"access_mode":"public","id":"b75fe16a3c7b8a0b4a272117d2e669af","_version":1,"secure_url":"https://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","folder_id":"c190ec1e8b89091d82749269dcc568ea96","url":"http://assets-dam.takeda.com/image/upload/v1675189033/legacy-dotcom/siteassets/ja-jp/home/takeda_logo.svg","type":"cloudinary.asset","format":"svg","version":1675189033,"public_id":"legacy-dotcom/siteassets/ja-jp/home/takeda_logo","bytes":3685,"width":1080,"uploaded_by":{"id":"553579438111562","type":"accesskey"},"height":599,"resource_type":"image","created_by":{"id":"553579438111562","type":"accesskey"},"metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2023-01-31T18:17:13Z","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"noIndexNoFollow":false,"scripts":[{"loadingStrategy":"beforeInteractive","title":"AIM-TAG","script":{"code":"\u003cscript defer nomodule src=\"https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer\u0026target=ie11\"\u003e\u003c/script\u003e\r\n\u003cscript defer type=\"module\" src=\"https://aim-tag.hcn.health/js/client.js?dl=aimDataLayer\"\u003e\u003c/script\u003e\r\n\u003cscript defer\u003e\r\nwindow.aimDataLayer = window.aimDataLayer || [];\r\nfunction aimTag() { aimDataLayer.push(arguments); }\r\n// Transition event is temporary during a limited period of time to allow us to pull application cache from Legacy AIM Reader (v2) over to AIM Tag (v4)\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'transition');\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'pageview');\r\n// If your contract includes signal, then callback will include personal information on the visitor\r\naimTag('b144cc67-6ce5-45f9-98b1-67b6555d21bd', 'signal', function(err, success) {\r\n    if (err) {\r\n        // This will occur if we disable your API Key\r\n        console.log(err);\r\n    } else {\r\n        console.log(success);\r\n        if (success.identity_type === \"AUT\") {\r\n            // Handle signal callback here\r\n        }\r\n    }\r\n});\r\n\u003c/script\u003e","language":"js","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"script":{"code":"\u003c!-- OneTrust Cookies Consent Notice start for takedaoncology.com --\u003e\n\u003cscript defer type=\"text/javascript\" src=\"https://cdn.cookielaw.org/consent/1c21da89-fd19-457f-a6d0-69a1c4fead2d/OtAutoBlock.js\" \u003e\u003c/script\u003e\n\u003cscript defer src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" data-document-language=\"true\" type=\"text/javascript\" charset=\"UTF-8\" data-domain-script=\"1c21da89-fd19-457f-a6d0-69a1c4fead2d\" \u003e\u003c/script\u003e\n\u003cscript defer type=\"text/javascript\"\u003e\nfunction OptanonWrapper() { }\n\u003c/script\u003e\n\u003c!-- OneTrust Cookies Consent Notice end for takedaoncology.com --\u003e","filename":"","language":"","highlightedLines":[2],"__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"loadingStrategy":"beforeInteractive","title":"OneTrust Script","__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"loadingStrategy":"beforeInteractive","title":"GTA Script","script":{"filename":"","language":"","code":"\u003c!-- Google Tag Manager --\u003e\n\u003cscript\u003e(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':\nnew Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],\nj=d.createElement(s),dl=l!='dataLayer'?'\u0026l='+l:'';j.async=true;j.src=\n'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);\n})(window,document,'script','dataLayer','GTM-WLM2GHB');\u003c/script\u003e\n\u003c!-- End Google Tag Manager --\u003e","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"title":"Matomo Tag Manager ","script":{"code":"\u003c!-- Matomo Tag Manager --\u003e\u003cscript\u003e\nvar _mtm = window._mtm = window._mtm || [];\n_mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'});\nvar d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0];\ng.async=true; g.src='https://cdn.matomo.cloud/takeda.matomo.cloud/container_8RFPFIX1.js'; s.parentNode.insertBefore(g,s);\n\u003c/script\u003e\u003c!-- End Matomo Tag Manager --\u003e","language":"","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"loadingStrategy":"beforeInteractive","__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"},{"loadingStrategy":"beforeInteractive","title":"CSS Hack for one trust","script":{"code":"\u003cstyle type=\"text/css\"\u003e #onetrust-consent-sdk svg {display: inline;} \u003c/style\u003e","filename":"","language":"","__metadata":{"modelName":"code","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"code"},"__metadata":{"modelName":"Script","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Script"}],"footer":{"logo":{"altText":"altText of the image","aspectRatio":"","priority":false,"url":{"context":{"custom":{"Language":"English","alt":"Takeda logo","caption":"Takeda logo"}},"height":256,"type":"cloudinary.asset","public_id":"migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257","format":"svg","version":1652260163,"width":720,"created_by":{"id":"553579438111562","type":"accesskey"},"url":"http://res.cloudinary.com/takeda/image/upload/v1652260163/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257.svg","uploaded_by":{"type":"accesskey","id":"553579438111562"},"bytes":3692,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1652260163/migration/dd376054054162cb1dd2807ef9d39eee5effe406-720x257.svg","access_mode":"public","resource_type":"image","created_at":"2022-05-11T09:09:23Z","tags":["Takeda Logo","Takeda","logo"],"__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"elementId":"","__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAECAMAAACA5l7/AAAAOVBMVEX4yMn86er4ycv0rrHuf4P3w8X50tNHcEz4zs/ugob73t/0rK763t/wlJfynaD86uv++PjzqKv1t7mDF9BrAAAADXRSTlP+Csdqs60qABrD7/7v1KBqGwAAAC1JREFUCNcdwgESABAIBMBLqJDw/8cydhZCnNpITAK1HrEWTJH3cZ9vRi34Sr0beAEtjhAsjAAAAABJRU5ErkJggg=="},"socialLinks":[{"url":"http://www.instagram.com/TakedaOncology","elementId":"","altText":"","icon":{"variant":"Instagram","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Instagram","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"altText":"facebook","icon":{"variant":"Facebook","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Facebook","url":"facebook.com/takedaoncology","elementId":"","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"url":"https://twitter.com/takedaoncology","elementId":"","altText":"","icon":{"variant":"Twitter","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"Twitter","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"},{"url":"https://www.linkedin.com/company/takedaoncology","elementId":"","altText":"","icon":{"variant":"LinkedIn","__metadata":{"modelName":"Icon","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Icon"},"style":"link","label":"LinkedIn","__metadata":{"modelName":"Social","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Social"}],"copyrightText":"All trademarks are the property of their respective owners.\n\n2025 Takeda Pharmaceuticals U.S.A., Inc.\n\nAll rights reserved. 01/23\n","__metadata":{"modelName":"DefaultFooter","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"2fteZ9Y1L8iF6RDIFNFz2C","createdAt":"2022-09-20T09:31:47Z","updatedAt":"2025-02-18T18:35:08Z"},"type":"DefaultFooter"},"header":{"logo":{"elementId":"","altText":"Takeda logo","aspectRatio":"","priority":false,"url":{"created_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"format":"svg","height":74,"version":1663597913,"width":207,"bytes":3077,"secure_url":"https://res.cloudinary.com/takeda/image/upload/v1663597913/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0.svg","public_id":"TAKEDA GLOBAL/takeda_logo_1_pf4uo0","uploaded_by":{"id":"655351c881d79bafeab2ef825c88fb","type":"user"},"url":"http://res.cloudinary.com/takeda/image/upload/v1663597913/TAKEDA%20GLOBAL/takeda_logo_1_pf4uo0.svg","type":"cloudinary.asset","access_mode":"public","metadata":{"epzciwdjuelllku8ngpo":["0001"]},"created_at":"2022-09-19T14:31:53Z","resource_type":"image","__metadata":{"modelName":"cloudinary.asset","projectId":"djvoabi3","source":"sourcebit-source-sanity"}},"__metadata":{"modelName":"ImageBlock","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ImageBlock","blurDataURL":"data:image/webp;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAECAMAAACA5l7/AAAARVBMVEX94OL4rK/2i4/4naD4oqX1h4v4p6r809X6ur395eb5tLf6wsT7ysz5tbj2jpL809X4rK/2kJT70tT5rK/6xcf5tbj6xsilREIhAAAAFnRSTlP9BjroKoNC+aHXb+7v5qWq56ar///+Wg1+4gAAADBJREFUCB0FwQkCABAIBMBFJDfF/59qBo7KEZmFHPxeDHAfHjFc1asaIlJuZs9qTh8gVgGrrAdbegAAAABJRU5ErkJggg=="},"searchLocationPlaceholder":"Search for a country","title":"Takeda Oncology","searchPageUrl":"/search","version":"v2","searchPlaceholder":"Search...","globalNavDefaultState":"expanded","scrolledDownColors":"takeda-colors","localNavDefaultState":"","defaultColors":"takeda-colors","__metadata":{"modelName":"DefaultHeader","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"9252634f-22e7-4042-ada9-0491a16c01b3","createdAt":"2022-07-21T14:11:36Z","updatedAt":"2023-06-08T11:31:39Z"},"type":"DefaultHeader"},"exitDisclaimer":{"isEnabled":true,"description":"You are now leaving Takedaoncology.com and entering a website that is not owned or controlled by Takeda. \n\nTakeda Oncology makes no representation as to the accuracy of the information contained on websites we do not own or control. Takeda Oncology does not recommend or endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.\n","title":"You are now leaving Takedaoncology.com","cancelButtonTitle":"Cancel","okButtonTitle":"Continue","whitelistedUrls":["assets-dam.takeda.com","takedaoncology.com","www.takedaoncology.com","takeda.com","content.takeda.com","www.takeda.com","takeda.info","www.takeda.info","takedacanada.com","www.takedacanada.com","takedajobs.com/oncology","www.takedajobs.com/oncology","clinicaltrials.takeda.com","www.clinicaltrials.takeda.com","velcade.com","www.velcade.com","velcade-hcp.com","www.velcade-hcp.com","ninlaro.com","www.ninlaro.com","ninlarohcp.com","www.ninlarohcp.com","exkivityhcp.com","www.exkivityhcp.com","exkivity.com","www.exkivity.com","iclusig.com","www.iclusig.com","alunbrig.com","www.alunbrig.com","tsupportportal.com","www.tsupportportal.com","here2assist.com","www.here2assist.com","secure.ethicspoint.com/domain/media/en/gui/28267/index.html","takeda.envisionpharma.com/vt_takeda","cookiepedia.co.uk/giving-consent-to-cookies","www.cookiepedia.co.uk/giving-consent-to-cookies","instagram.com/TakedaOncology","www.instagram.com/TakedaOncology","twitter.com/takedaoncology","www.twitter.com/takedaoncology","facebook.com/takedaoncology","www.facebook.com/takedaoncology","linkedin.com/company/takedaoncology","www.linkedin.com/company/takedaoncology"],"__metadata":{"modelName":"ExitDisclaimer","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"ExitDisclaimer"},"globalLanguages":[{"displayName":"English","links":[{"showIcon":false,"url":"/about/","icon":"arrowRight","iconPosition":"right","label":"About","elementId":"","altText":"About Takeda Oncology","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"showIcon":false,"label":"Science","icon":"arrowRight","altText":"Science","iconPosition":"right","url":"/science/","elementId":"","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"icon":"arrowRight","showIcon":false,"label":"Medicines","url":"/medicines/","elementId":"","altText":"Medicines","iconPosition":"right","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"label":"Patients","altText":"Patients","showIcon":false,"url":"/patients/","elementId":"","icon":"arrowRight","iconPosition":"right","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"iconPosition":"right","url":"/partnerships/","elementId":"","icon":"arrowRight","showIcon":false,"altText":"Partnerships","label":"Partnerships","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"icon":"arrowRight","url":"/newsroom/","altText":"Newsroom","label":"Newsroom ","showIcon":false,"iconPosition":"right","elementId":"","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"label":"Investors ","showIcon":false,"elementId":"","icon":"arrowRight","iconPosition":"right","url":"https://www.takeda.com/investors/","altText":"Investors","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"}],"languageCode":"en","isDefault":false,"additionalLinks":[{"altText":"Privacy Notice","icon":"LinkExternal","iconPosition":"right","url":"https://www.takeda.com/privacy-notice/","elementId":"","label":"Privacy Notice","showIcon":true,"__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"altText":"","elementId":"","icon":"LinkExternal","showIcon":true,"url":"https://www.takeda.com/terms-of-use/","iconPosition":"right","label":"Terms of Use","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"showIcon":false,"url":"/social-media-policy/","elementId":"","altText":"Social Media Policy","icon":"arrowRight","iconPosition":"right","label":"Social Media Policy","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"},{"icon":"arrowRight","iconPosition":"right","showIcon":false,"url":"/about/contact-us/","elementId":"","label":"Contact Us","altText":"","__metadata":{"modelName":"Link","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"Link"}],"__metadata":{"modelName":"GlobalLanguage","projectId":"djvoabi3","source":"sourcebit-source-sanity"},"type":"GlobalLanguage"}],"__metadata":{"modelName":"Config","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"IV5sQe0KJfPcurPYxLZQeL","createdAt":"2022-07-21T14:11:21Z","updatedAt":"2025-03-19T12:34:30Z"},"type":"Config"},"defaultTheme":{"colorSecondary":"#ffffff","colorSecondaryContrast":"#34373f","colorPrimaryActive":"#891515","colorDarkGrey":"#34373f","colorPrimaryContrast":"#ffffff","colorMediumGreyContrast":"#ffffff","colorMediumGrey":"#8289A5","colorPrimary":"#bd120a","colorPrimaryActiveContrast":"#ffffff","colorLightGreyContrast":"#34373f","colorDarkGreyContrast":"#ffffff","colorLightGrey":"#edf2f4","textColor":"#333333","__metadata":{"modelName":"ThemeStyle","projectId":"djvoabi3","source":"sourcebit-source-sanity","id":"2c32cbf6-3c2c-45c9-ba61-912e076f9e03","createdAt":"2022-09-02T06:01:20Z","updatedAt":"2023-06-08T11:31:22Z"},"type":"ThemeStyle"},"draftMode":null},"__N_SSG":true},"page":"/[[...slug]]","query":{},"buildId":"K3VXqlfsDZXTEXydIA4dC","isFallback":false,"dynamicIds":[39099,11735,40982,28378,11467,44676,48212,18079,30738,20675,286,42066,43829,47588,83477,89362,69838,90288,33644,47707,14492,83559,33439,45455,46978,68845,79634,39413,53085,42600,60812,97871,94009,32255,86211,26166,28211,1118,95847,23851,61078,60283,65298,83029,5866,75724,47133,46362,19457],"gsp":true,"scriptLoader":[]}</script></body></html>